isoniazid and Chemical and Drug Induced Liver Injury studies

Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).

Chemical and Drug Induced Liver Injury: A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.

Research Excerpts

Excerpt	Relevance	Reference
"Hepatotoxicity associated with isoniazid preventive therapy (IPT) and antiretroviral therapy (ART) has not been well studied in severely immunosuppressed people with HIV."	9.27	Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial. ( Bisson, GP; Gupta, A; Hosseinipour, MC; Hughes, MD; Kidonge, KK; Kumwenda, J; Lavenberg, JA; Miyahara, S; Ngongondo, M; Nyirenda, M; Sun, X; Torres, TS, 2018)
"This study is a pharmacogenetic clinical trial designed to clarify whether the N-acetyltransferase 2 gene (NAT2) genotype-guided dosing of isoniazid improves the tolerability and efficacy of the 6-month four-drug standard regimen for newly diagnosed pulmonary tuberculosis."	9.17	NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. ( Azuma, J; Fujio, Y; Kamimura, S; Kawase, I; Kubota, R; Nagai, T; Ohno, M; Okuda, Y; Takashima, T; Tsuyuguchi, K; Yokota, S, 2013)
"Treatment of latent tuberculosis infection with isoniazid for 9 months is complicated by poor patient adherence and the need for close follow-up of side effects, especially hepatotoxicity."	9.13	Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. ( Al Jahdali, H; Benedetti, A; Dion, MJ; Gardam, M; Hoeppner, V; Khan, K; Long, R; Memish, Z; Menzies, D; Schwartzman, K; Trajman, A; Yang, J, 2008)
"The mainstay therapy for latent tuberculosis infection is a 9-month regimen of daily isoniazid (9H) and a 3-month regimen of 12 once-weekly doses of isoniazid and rifapentine (3HP)."	9.12	Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis. ( Chang, TE; Huang, YH; Huang, YS; Perng, CL; Tseng, SY, 2021)
"To compare the incidence of severe hepatitis in HIV-infected patients receiving rifampicin plus pyrazinamide (RZ) for antituberculosis prophylaxis with that of patients receiving a conventional isoniazid-based regime for 6 to 12 months (6-12H)."	8.86	[Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials]. ( Camacho, A; Castón, JJ; Gallo, M; García-Lázaro, M; Kindelán, JM; Natera, C; Pérez-Camacho, I; Rivero, A; Torre-Cisneros, J, 2010)
"To examine chronic viral hepatitis (CVH) as a risk factor for hepatotoxicity during isoniazid (INH) treatment for latent tuberculosis infection (LTBI)."	8.85	The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection. ( Bliven, EE; Podewils, LJ, 2009)
"Two patients with liver failure secondary to isoniazid hepatotoxicity were successfully treated with orthotopic liver transplantation."	8.79	Treatment of hepatic failure secondary to isoniazid hepatitis with liver transplantation. ( Esquivel, CO; Farrell, FJ; Imperial, JC; Keeffe, EB; Man, KM, 1994)
"We aimed to determine overall incidence of severe and mild isoniazid (INH) hepatotoxicity and outcome of hepatotoxicity in children who were receiving INH for latent tuberculosis."	8.02	Isoniazid-induced hepatotoxicity in children with latent tuberculosis infection. ( Aksay, A; Aktürk, H; Apa, H; Bayram, N; Can, D; Devrim, F; Devrim, İ, 2021)
"[Purpose] To investigate the frequency and risk factors of severe liver dysfunction in patients receiving isoniazid (INH) mono-therapy for latent tuberculosis infection (LTBI)."	7.83	[FREQUENCY AND RISK FACTORS OF SEVERE LIVER DYSFUNCTION IN ISONIAZID MONO-THERAPY FOR LATENT TUBERCULOSIS INFECTION]. ( Ito, K, 2016)
"To investigate the clinical characteristics, adverse drug reactions, and outcomes of the oldest old patients (aged ≥80 years) with tuberculosis (TB) treated with rifampicin, isoniazid, and pyrazinamide (RIP)-containing regimens."	7.83	The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide. ( Chang, PJ; Cheng, CW; Chou, YL; Lin, HS; Lin, JC; Lin, MS; Ye, JJ, 2016)
"Treating latent tuberculosis infection is a strategy for eliminating tuberculosis, and isoniazid is recommended as preventive therapy."	7.81	Isoniazid-induced acute liver failure during preventive therapy for latent tuberculosis infection. ( Hamana, S; Matsuoka, S; Miyazawa, S; Moriyama, M; Nagai, S; Nakamura, H; Nirei, K, 2015)
"Isoniazid (INH)-induced hepatotoxicity remains one of the most common causes of drug-induced idiosyncratic liver injury and liver failure."	7.80	Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure. ( Lee, WM; Metushi, IG; Sanders, C; Uetrecht, J, 2014)
"Short-course directly observed isoniazid plus rifapentine (INH/RPT) combination could have potential advantages over a standard 9-month INH regimen for the treatment of latent tuberculosis infection in solid-organ transplant (SOT) candidates."	7.80	Short-course isoniazid plus rifapentine directly observed therapy for latent tuberculosis in solid-organ transplant candidates. ( de Castilla, DL; Jain, R; Limaye, AP; Narita, M; Rakita, RM; Spitters, CE, 2014)
"Isoniazid (INH) therapy is associated with a significant incidence of idiosyncratic liver failure."	7.80	IgG3 is the dominant subtype of anti-isoniazid antibodies in patients with isoniazid-induced liver failure. ( Lee, WM; Metushi, IG; Uetrecht, J, 2014)
" A tuberculin skin test was positive, we started anti-tuberculosis (TB) chemoprophylaxis with isoniazid (INH)."	7.78	Development of interstitial pneumonia in a patient with rheumatoid arthritis induced by isoniazid for tuberculosis chemoprophylaxis. ( Ito, M; Izumi, Y; Kakugawa, T; Kinoshita, A; Migita, K; Miyagawa, K; Miyashita, T; Sasaki, E; Umeno, T, 2012)
"To compare rates of treatment interruption because of side effects and completion rates between subjects treated for latent tuberculosis infection (LTBI) by isoniazid (INH) for 6 months and subjects treated with rifampicin (RIF) for 4 months."	7.77	Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis. ( Bridevaux, PO; Fresard, I; Janssens, JP; Rochat, T, 2011)
"Since the 1960s, 6 to 9 months of isoniazid (INH) has been the mainstay of treatment for latent tuberculosis infection (LTBI), but its application has been limited by concerns about the toxicity of INH and the long duration of treatment."	7.76	Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008. ( , 2010)
" The acetylhydrazine metabolite was found to be much less cytotoxic than hydrazine in this hepatocyte inflammation model."	7.74	Role of hydrazine in isoniazid-induced hepatotoxicity in a hepatocyte inflammation model. ( Mashregi, M; O'Brien, PJ; Tafazoli, S, 2008)
"To determine the overall incidence of isoniazid (INH) hepatotoxicity in a public health tuberculosis clinic over a 7-year period, and to determine if systematic, limited aspartate aminotransferase (AST) monitoring would be of benefit in detecting INH hepatotoxicity."	7.73	Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. ( Chrisman, CR; Fountain, FF; Self, TH; Tolley, E, 2005)
"Since the introduction of new recommendations for the treatment of latent tuberculosis infection (LTB1) disregarding age as a limitation, increasing numbers of older individuals are expected to undergo treatment with isoniazid for the prevention of tuberculosis, raising the potential for an increase in isoniazid hepatotoxicity."	7.73	Assessment of age-related isoniazid hepatotoxicity during treatment of latent tuberculosis infection. ( Aziz, H; Debari, VA; Ismail, M; Khan, MA; Shubair, M, 2006)
"Severe liver injury has been attributed to preventive treatment of latent tuberculosis infection with a 2-month course of rifampin-pyrazinamide."	7.72	Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. ( Baars, H; Borgdorff, M; Cobelens, F; Kalisvaart, N; Keizer, S; Kik, S; Mensen, M; Trompenaars, MC; van Gerven, P; van Hest, R, 2004)
"In 2000, results of a multinational trial demonstrated that a 2-month course of rifampin and pyrazinamide (RZ) was as effective as isoniazid (INH) in reducing tuberculosis in human immunodeficiency virus (HIV)-infected individuals with latent tuberculosis infection (LTBI)."	7.72	Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? ( Chaisson, RE; Cohn, DL; Gordin, FM; Matts, JP; O'Brien, RJ, 2004)
"Treatment of latent Mycobacterium tuberculosis infection with isoniazid can cause hepatotoxicity, but the risk of isoniazid-associated hepatotoxicity among persons coinfected with hepatitis C virus (HCV) is unknown."	7.71	Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. ( Astemborski, J; Bonds, M; Graham, NM; Madison, A; Sadaphal, P; Sheely, L; Sterling, TR; Thomas, DL; Vlahov, D, 2001)
"Isoniazid preventive therapy for latent tuberculosis (TB) infection has been debated because of the risk of hepatotoxicity."	7.70	Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. ( Buskin, SE; Goldberg, SV; Nolan, CM, 1999)
"Noncaseating granulomatous hepatitis may be caused by a variety of drugs, but we have not found, by computer search of the literature, a previous describe of granulomatous hepatitis associated with pyrazinamide."	7.69	Pyrazinamide-induced granulomatous hepatitis. ( Buyanowsky, G; Dan, M; Knobel, B; Zaidel, L, 1997)
"Results are presented of the incidence of hepatitis, nearly always with jaundice, among 1686 patients in clinical trials of the treatment of spinal tuberculosis, of tuberculosis meningitis and of pulmonary tuberculosis with short-course regimens containing rifampicin, isoniazid, streptomycin and pyrazinamide."	7.67	Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. ( Janardhanam, B; Parthasarathy, R; Ramachandran, P; Santha, T; Sarma, GR; Sivasubramanian, S; Somasundaram, PR; Tripathy, SP, 1986)
"Five children with tuberculosis were treated with isoniazid (20 mg."	7.65	[Toxic hepatitis caused by rifampin and isoniazid in treatment of tuberculosis (author's transl)]. ( Abeledo Mezquita, G; Otero Reigada, MC, 1977)
"The main aim of this study is to determine the demographics, compliance, completion rates and adverse events of patients on preventive therapy (PT) for LTBI at our institution."	6.82	Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection. ( Goldberg, HF; Gray, EL, 2016)
" We aimed to determine whether the INH/RPT-3 regimen had similar or lesser rates of adverse events compared to other LTBI regimens, namely INH for 9 months, INH for 6 months, rifampin for 3 to 4 months, and rifampin plus INH for 3 to 4 months."	6.58	A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection. ( Alvarez, GG; Barbeau, P; Hamel, C; Hutton, B; Pease, C; Skidmore, B; Wolfe, D; Yazdi, F, 2018)
"Renal transplant candidates (RTC) with latent tuberculosis infection (LTBI) are at significant risk for tuberculosis reactivation."	5.46	Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates. ( Abbo, LM; Camargo, JF; Morris, MI; Rosa, R; Simkins, J, 2017)
"She presented repetitive generalized convulsions with metabolic acidosis, treated with diazepam and 7."	5.31	[Acute isoniazid poisoning presenting convulsion and liver dysfunction]. ( Hamabe, Y; Kiyota, K, 2001)
"Hepatotoxicity associated with isoniazid preventive therapy (IPT) and antiretroviral therapy (ART) has not been well studied in severely immunosuppressed people with HIV."	5.27	Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial. ( Bisson, GP; Gupta, A; Hosseinipour, MC; Hughes, MD; Kidonge, KK; Kumwenda, J; Lavenberg, JA; Miyahara, S; Ngongondo, M; Nyirenda, M; Sun, X; Torres, TS, 2018)
"This study is a pharmacogenetic clinical trial designed to clarify whether the N-acetyltransferase 2 gene (NAT2) genotype-guided dosing of isoniazid improves the tolerability and efficacy of the 6-month four-drug standard regimen for newly diagnosed pulmonary tuberculosis."	5.17	NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. ( Azuma, J; Fujio, Y; Kamimura, S; Kawase, I; Kubota, R; Nagai, T; Ohno, M; Okuda, Y; Takashima, T; Tsuyuguchi, K; Yokota, S, 2013)
" According to the findings of the present study, all 3 of the potentially hepatotoxic drugs (isoniazid, rifampicin, and pyrazinamide) can be reintroduced simultaneously at full dosage safely from day 1, especially for patients with bilateral extensive pulmonary tuberculosis, to halt disease transmission or to treat patients with life-threatening tuberculosis."	5.14	Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. ( Jayaswal, A; Makharia, G; Mohan, A; Sarda, P; Sharma, SK; Singh, S; Singla, R; Sreenivas, V, 2010)
"Treatment of latent tuberculosis infection with isoniazid for 9 months is complicated by poor patient adherence and the need for close follow-up of side effects, especially hepatotoxicity."	5.13	Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. ( Al Jahdali, H; Benedetti, A; Dion, MJ; Gardam, M; Hoeppner, V; Khan, K; Long, R; Memish, Z; Menzies, D; Schwartzman, K; Trajman, A; Yang, J, 2008)
"The mainstay therapy for latent tuberculosis infection is a 9-month regimen of daily isoniazid (9H) and a 3-month regimen of 12 once-weekly doses of isoniazid and rifapentine (3HP)."	5.12	Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis. ( Chang, TE; Huang, YH; Huang, YS; Perng, CL; Tseng, SY, 2021)
"A history of alcoholism is often regarded as a relative contraindication to the use of isoniazid and rifampin in patients with tuberculosis."	5.05	Rifampin-isoniazid therapy of alcoholic and nonalcoholic tuberculous patients in a U.S. Public Health Service Cooperative Therapy Trial. ( Banner, AS; Cross, FS; Long, MW; Snider, DE, 1980)
"Although isoniazid (INH) has been successful in treating Tuberculosis (TB) since its introduction in 1952, there has been continual reports of drug-associated hepatotoxicity in TB patients."	5.01	Pharmacokinetics of isoniazid: The good, the bad, and the alternatives. ( Addison, AP; Erwin, ER; John, SF; Olaleye, OA; Rosell, RC, 2019)
"Efavirenz (EFV) and rifampicin-isoniazid (RH) are cornerstone drugs in human immunodeficiency virus (HIV)-tuberculosis (TB) coinfection treatment but with complex drug interactions, efficacy and safety challenges."	4.98	Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review. ( Atwine, D; Bonnet, M; Taburet, AM, 2018)
"To compare the incidence of severe hepatitis in HIV-infected patients receiving rifampicin plus pyrazinamide (RZ) for antituberculosis prophylaxis with that of patients receiving a conventional isoniazid-based regime for 6 to 12 months (6-12H)."	4.86	[Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials]. ( Camacho, A; Castón, JJ; Gallo, M; García-Lázaro, M; Kindelán, JM; Natera, C; Pérez-Camacho, I; Rivero, A; Torre-Cisneros, J, 2010)
"Isoniazid (INH) has been the mainstay of treatment of latent tuberculosis infection for almost 50 years."	4.86	Treatment of latent tuberculosis infection: An update. ( Lobue, P; Menzies, D, 2010)
"To examine chronic viral hepatitis (CVH) as a risk factor for hepatotoxicity during isoniazid (INH) treatment for latent tuberculosis infection (LTBI)."	4.85	The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection. ( Bliven, EE; Podewils, LJ, 2009)
"The cornerstone of tuberculosis management is a 6-month course of isoniazid, rifampicin, pyrazinamide and ethambutol."	4.84	Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. ( Aarnoutse, RE; Boeree, MJ; de Lange, WC; Dekhuijzen, R; Tostmann, A; van der Ven, AJ, 2008)
"Isoniazid, pyrazinamide and rifampicin have hepatotoxic potential, and can lead to such reactions during antituberculosis chemotherapy."	4.83	Antituberculosis drugs and hepatotoxicity. ( Leung, CC; Yew, WW, 2006)
"Two patients with liver failure secondary to isoniazid hepatotoxicity were successfully treated with orthotopic liver transplantation."	4.79	Treatment of hepatic failure secondary to isoniazid hepatitis with liver transplantation. ( Esquivel, CO; Farrell, FJ; Imperial, JC; Keeffe, EB; Man, KM, 1994)
"Isoniazid(INH, H) has been a key drug for treating drug-susceptible tuberculosis (TB) for nearly seventy years."	4.12	[Association between isoniazid induced hepatotoxicity and host N-acetyltransferase 2 polymorphisms]. ( Guo, JQ; Tang, S; Yan, XF; Yang, S, 2022)
"We aimed to determine overall incidence of severe and mild isoniazid (INH) hepatotoxicity and outcome of hepatotoxicity in children who were receiving INH for latent tuberculosis."	4.02	Isoniazid-induced hepatotoxicity in children with latent tuberculosis infection. ( Aksay, A; Aktürk, H; Apa, H; Bayram, N; Can, D; Devrim, F; Devrim, İ, 2021)
" The secondary objective was to determine the overall incidence of hepatitis in children on Anti tubercular treatment (ATT) and isoniazid prophylactic therapy (IPT)."	3.91	Revised Antituberculosis Drug Doses and Hepatotoxicity in HIV Negative Children. ( Indumathi, CK; Jain, S; Krishnamurthy, S; Sethuraman, A, 2019)
"Isoniazid monotherapy for six or nine months and the combination of isoniazid and rifampicin for three or four months are the most used regimens for treating latent tuberculosis."	3.88	Latent tuberculosis in childhood: tolerability of two different therapeutic approaches. ( Bianchi, L; Chiappini, E; Cordola, C; de Martino, M; Galli, L; Montagnani, C; Piccini, P; Sollai, S; Tersigni, C; Venturini, E, 2018)
"Isoniazid (INH) is part of the first-line-therapy for tuberculosis (TB) but can cause drug-induced liver injury (DILI)."	3.85	Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients. ( Aminkeng, F; Brunham, LR; Chan, SL; Chee, CBE; Chua, APG; Gan, SH; Jin, S; Loh, M; Wang, YT, 2017)
"Combination of isoniazid (INH) and rifampicin (RFP) causes liver injury frequently among tuberculosis patients."	3.85	Involvement of protoporphyrin IX accumulation in the pathogenesis of isoniazid/rifampicin-induced liver injury: the prevention of curcumin. ( Deng, Y; Guo, Y; He, L; Li, C; Peng, W; Zuo, C, 2017)
"[Purpose] To investigate the frequency and risk factors of severe liver dysfunction in patients receiving isoniazid (INH) mono-therapy for latent tuberculosis infection (LTBI)."	3.83	[FREQUENCY AND RISK FACTORS OF SEVERE LIVER DYSFUNCTION IN ISONIAZID MONO-THERAPY FOR LATENT TUBERCULOSIS INFECTION]. ( Ito, K, 2016)
"To investigate the clinical characteristics, adverse drug reactions, and outcomes of the oldest old patients (aged ≥80 years) with tuberculosis (TB) treated with rifampicin, isoniazid, and pyrazinamide (RIP)-containing regimens."	3.83	The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide. ( Chang, PJ; Cheng, CW; Chou, YL; Lin, HS; Lin, JC; Lin, MS; Ye, JJ, 2016)
"Isoniazid (INH) is the most effective drug used as a first-line tuberculosis (TB) treatment besides rifampicin, pyrazinamide, and ethambutol."	3.83	NAT2 Genotypes in Moroccan Patients with Hepatotoxicity Due to Antituberculosis Drugs. ( Bencheikh, RS; Bourkadi, JE; El Bouazzi, O; Guaoua, S; Hammi, S; Ratbi, I; Sefiani, A; Tebaa, A, 2016)
" We conducted this study to evaluate the association between polymorphisms of CYP2E1, Isoniazid (INH) concentration and the acetylator status of INH in cases of Indonesian tuberculosis patients with drug-induced liver disease (DILI)."	3.83	CYP2E1 polymorphism, acetylator profiles and drug-induced liver injury incidence of Indonesian tuberculosis patients. ( Atthobari, J; Darmawan, E; Irham, LM; Mulyani, UA; Perwitasari, DA, 2016)
"We prospectively examined the incidence of drug-induced hepatitis in 2070 patients treated for TB with the standard regimen based on 6 months of rifampicin (R, RMP) and isoniazid (H, INH), with 2 months of initial pyrazinamide (Z, PZA) and ethambutol (E, EMB), over a 30-year period from 1981 to 2010, in Blackburn, UK."	3.83	Drug-related hepatitis in patients treated with standard anti-tuberculosis chemotherapy over a 30-year period. ( Bright-Thomas, RJ; Gondker, AR; Morris, J; Ormerod, LP, 2016)
"Treating latent tuberculosis infection is a strategy for eliminating tuberculosis, and isoniazid is recommended as preventive therapy."	3.81	Isoniazid-induced acute liver failure during preventive therapy for latent tuberculosis infection. ( Hamana, S; Matsuoka, S; Miyazawa, S; Moriyama, M; Nagai, S; Nakamura, H; Nirei, K, 2015)
"Isoniazid (INH)-induced hepatotoxicity remains one of the most common causes of drug-induced idiosyncratic liver injury and liver failure."	3.80	Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure. ( Lee, WM; Metushi, IG; Sanders, C; Uetrecht, J, 2014)
"Short-course directly observed isoniazid plus rifapentine (INH/RPT) combination could have potential advantages over a standard 9-month INH regimen for the treatment of latent tuberculosis infection in solid-organ transplant (SOT) candidates."	3.80	Short-course isoniazid plus rifapentine directly observed therapy for latent tuberculosis in solid-organ transplant candidates. ( de Castilla, DL; Jain, R; Limaye, AP; Narita, M; Rakita, RM; Spitters, CE, 2014)
"To compare the free and total plasma drug concentrations of rifampicin (RMP), isoniazid and pyrazinamide in subjects with or without anti-tuberculosis drug-induced hepatotoxicity (DIH)."	3.80	Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity. ( Biswas, A; Makharia, GK; Satyaraddi, A; Sharma, A; Sharma, SK; Singh, S; Sinha, S; Sirohiwal, A; Velpandian, T; Vishnubhatla, S, 2014)
"Isoniazid (INH) therapy is associated with a significant incidence of idiosyncratic liver failure."	3.80	IgG3 is the dominant subtype of anti-isoniazid antibodies in patients with isoniazid-induced liver failure. ( Lee, WM; Metushi, IG; Uetrecht, J, 2014)
"This study aims to assess whether NAT2 genotype affects susceptibility to moderate to severe liver injury in patients undergoing drug treatment for tuberculosis with isoniazid-containing regimens."	3.80	N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group. ( Ahmed, MU; Aithal, GP; Al Maruf, A; Daly, AK; Day, CP; Hasnat, A; Ng, CS; Pirmohamed, M, 2014)
"To assess the cost-effectiveness ratio of rifampin for 4 months and isoniazid for 6 months in contacts with latent tuberculosis infection."	3.79	Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection. ( Clotet, L; Domínguez, A; Ferrer, A; Garrido, P; Pina, JM; Sala, MR; Salleras, L, 2013)
" A tuberculin skin test was positive, we started anti-tuberculosis (TB) chemoprophylaxis with isoniazid (INH)."	3.78	Development of interstitial pneumonia in a patient with rheumatoid arthritis induced by isoniazid for tuberculosis chemoprophylaxis. ( Ito, M; Izumi, Y; Kakugawa, T; Kinoshita, A; Migita, K; Miyagawa, K; Miyashita, T; Sasaki, E; Umeno, T, 2012)
"Antituberculosis drug-induced hepatitis attributed to isoniazide (INH) is one of the most prevalent drug-induced liver injuries."	3.78	Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis. ( Ben Mahmoud, L; Ghozzi, H; Hachicha, H; Hakim, A; Hammami, S; Kamoun, A; Makni, H; Sahnoun, Z; Zalila, N; Zeghal, K, 2012)
"During the period of observation, therapy for latent tuberculosis was dispensed to 9145 residents, of whom 95% started isoniazid and 5% started rifampin."	3.77	Adverse events associated with treatment of latent tuberculosis in the general population. ( Bartlett, G; Menzies, D; Schwartzman, K; Smith, BM, 2011)
"To compare rates of treatment interruption because of side effects and completion rates between subjects treated for latent tuberculosis infection (LTBI) by isoniazid (INH) for 6 months and subjects treated with rifampicin (RIF) for 4 months."	3.77	Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis. ( Bridevaux, PO; Fresard, I; Janssens, JP; Rochat, T, 2011)
"A case-control study including Caucasian patients with tuberculosis (TB) treated with isoniazid, rifampicin and pyrazinamide."	3.77	N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians. ( Agúndez, JA; Botana-Rial, M; Constenla, L; Fernández-Villar, A; Leiro-Fernandez, V; Valverde, D; Vázquez-Gallardo, R, 2011)
"Treatment of latent tuberculosis infection (LTBI) generally includes isoniazid (INH), a drug that can cause serious hepatotoxicity."	3.76	Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity. ( Brooks-Wilson, A; Cook, VJ; Elwood, K; Fitzgerald, JM; Halaschek-Wiener, J; Marra, F; Richardson, K; Tang, M; Yamada, S, 2010)
"Since the 1960s, 6 to 9 months of isoniazid (INH) has been the mainstay of treatment for latent tuberculosis infection (LTBI), but its application has been limited by concerns about the toxicity of INH and the long duration of treatment."	3.76	Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008. ( , 2010)
"The standard antitubercular treatment (ATT), which consists of isoniazid (INH), rifampicin (RIF), ethambutol, and pyrazinamide (PZA), is the best available treatment for tuberculosis (TB)."	3.76	Acute liver failure due to antitubercular therapy: Strategy for antitubercular treatment before and after liver transplantation. ( Antonini, TM; Antoun, F; Azoulay, D; Castaing, D; Delvart, V; Escaut, L; Ichai, P; Saliba, F; Samuel, D; Sebagh, M, 2010)
"To investigate retrospectively the incidence of drug-induced hepatitis (DIH) caused by antituberculosis drugs including isoniazid (INH), rifampicin (RFP), with and without pyrazinamide (PZA), and to evaluate risk factors for DIH in tuberculosis patients complicated with chronic hepatitis (CH)."	3.74	[Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis]. ( Akagawa, S; Ariga, H; Kaneko, Y; Kawabe, Y; Kawashima, M; Kunogi, M; Kurashima, A; Machida, K; Masuda, K; Matsui, H; Matsui, Y; Nagai, H; Nagayama, N; Oshima, N; Shimada, M; Suzuki, J; Tamura, A; Toyoda, E; Yotsumoto, H, 2008)
" The acetylhydrazine metabolite was found to be much less cytotoxic than hydrazine in this hepatocyte inflammation model."	3.74	Role of hydrazine in isoniazid-induced hepatotoxicity in a hepatocyte inflammation model. ( Mashregi, M; O'Brien, PJ; Tafazoli, S, 2008)
"Tuberculosis is treated with a group of drugs that need to be used over a long period of time and isoniazid is the major drug in this group."	3.74	Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests. ( Aktoğu, S; Bozok Cetintaş, V; Erer, OF; Eroğlu, Z; Kosova, B; Ozdemir, I; Topçuoğlu, N, 2008)
"To determine whether inactive hepatitis B surface antigen (HBsAg) carriers are at a higher risk of drug-induced hepatotoxicity than control subjects during antituberculosis treatment with standard short-course regimens of isoniazid, rifampin, ethambutol, and/or pyrazinamide."	3.73	Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. ( Choi, MS; Chung, MP; Kim, H; Koh, WJ; Kwon, OJ; Lee, BH; Suh, GY, 2005)
"To determine the overall incidence of isoniazid (INH) hepatotoxicity in a public health tuberculosis clinic over a 7-year period, and to determine if systematic, limited aspartate aminotransferase (AST) monitoring would be of benefit in detecting INH hepatotoxicity."	3.73	Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. ( Chrisman, CR; Fountain, FF; Self, TH; Tolley, E, 2005)
"Since the introduction of new recommendations for the treatment of latent tuberculosis infection (LTB1) disregarding age as a limitation, increasing numbers of older individuals are expected to undergo treatment with isoniazid for the prevention of tuberculosis, raising the potential for an increase in isoniazid hepatotoxicity."	3.73	Assessment of age-related isoniazid hepatotoxicity during treatment of latent tuberculosis infection. ( Aziz, H; Debari, VA; Ismail, M; Khan, MA; Shubair, M, 2006)
"Severe liver injury has been attributed to preventive treatment of latent tuberculosis infection with a 2-month course of rifampin-pyrazinamide."	3.72	Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. ( Baars, H; Borgdorff, M; Cobelens, F; Kalisvaart, N; Keizer, S; Kik, S; Mensen, M; Trompenaars, MC; van Gerven, P; van Hest, R, 2004)
"In 2000, results of a multinational trial demonstrated that a 2-month course of rifampin and pyrazinamide (RZ) was as effective as isoniazid (INH) in reducing tuberculosis in human immunodeficiency virus (HIV)-infected individuals with latent tuberculosis infection (LTBI)."	3.72	Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? ( Chaisson, RE; Cohn, DL; Gordin, FM; Matts, JP; O'Brien, RJ, 2004)
"Treatment of latent Mycobacterium tuberculosis infection with isoniazid can cause hepatotoxicity, but the risk of isoniazid-associated hepatotoxicity among persons coinfected with hepatitis C virus (HCV) is unknown."	3.71	Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. ( Astemborski, J; Bonds, M; Graham, NM; Madison, A; Sadaphal, P; Sheely, L; Sterling, TR; Thomas, DL; Vlahov, D, 2001)
"Isoniazid prophylaxis for 12 months effectively prevents tuberculosis in HIV-infected persons and may decrease the incidence of other HIV-related disease and mortality."	3.70	Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis. ( Rose, DN, 1998)
" - The LTT was performed with isoniazid and rifampicin in 15 tuberculosis and 2 MOTT (Mycobacteria other than tuberculosis)-infection patients who suffered drug reactions, in 23 patients without any adverse reactions, in 7 controls previously exposed to antituberculous drugs, and in 14 controls who had never been exposed."	3.70	Lymphocyte transformation test for the evaluation of adverse effects of antituberculous drugs. ( Greinert, U; Müller-Quernheim, J; Schlaak, M; Schreiber, J; Zissel, G, 1999)
"Isoniazid preventive therapy for latent tuberculosis (TB) infection has been debated because of the risk of hepatotoxicity."	3.70	Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. ( Buskin, SE; Goldberg, SV; Nolan, CM, 1999)
"To describe the clinical and demographic characteristics of fatal hepatitis due to single-drug isoniazid preventive therapy for tuberculosis, we did a survey of cases from state health departments, published case reports, and reports to the Centers for Disease Control and Prevention from 1970 to 1992."	3.69	Isoniazid-related fatal hepatitis. ( Millard, PS; Reade-Christopher, SJ; Weber, DJ; Wilcosky, TC, 1996)
"Noncaseating granulomatous hepatitis may be caused by a variety of drugs, but we have not found, by computer search of the literature, a previous describe of granulomatous hepatitis associated with pyrazinamide."	3.69	Pyrazinamide-induced granulomatous hepatitis. ( Buyanowsky, G; Dan, M; Knobel, B; Zaidel, L, 1997)
"Isoniazid chemoprophylaxis effectively prevents the development of active infectious tuberculosis."	3.69	Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. ( Owens, DK; Salpeter, EE; Salpeter, SR; Sanders, GD, 1997)
"Serologic markers for hepatitis viruses were studied in 40 children who developed acute hepatitis during antituberculosis therapy with rifampin and isoniazid, with the aim of assessing the contributory role of these viruses toward producing hepatic injury."	3.68	Hepatotoxicity of rifampin and isoniazid. Is it all drug-induced hepatitis? ( Govil, YC; Kumar, A; Mehotra, R; Misra, PK; Rana, GS, 1991)
"Daily administration of isoniazid for one year to persons infected with Mycobacterium tuberculosis is effective in considerably reducing the risk of disease."	3.67	Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy. ( Caras, GJ; Koplan, JP; Snider, DE, 1986)
"4 years) who have been treated with isoniazid for prevention of tuberculosis, data from 1935 were suitable for analysis."	3.67	Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons. ( Abraham, JH; Harrison, RW; Stead, WW; To, T, 1987)
"Results are presented of the incidence of hepatitis, nearly always with jaundice, among 1686 patients in clinical trials of the treatment of spinal tuberculosis, of tuberculosis meningitis and of pulmonary tuberculosis with short-course regimens containing rifampicin, isoniazid, streptomycin and pyrazinamide."	3.67	Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. ( Janardhanam, B; Parthasarathy, R; Ramachandran, P; Santha, T; Sarma, GR; Sivasubramanian, S; Somasundaram, PR; Tripathy, SP, 1986)
"We used decision analysis to determine the benefits and risks of preventive therapy with isoniazid for young adults whose only risk factor for the development of active tuberculosis was a positive tuberculin skin test."	3.66	Should young adults with a positive tuberculin test take isoniazid? ( Aronson, MD; Delbanco, TL; Taylor, WC, 1981)
"Five children with tuberculosis were treated with isoniazid (20 mg."	3.65	[Toxic hepatitis caused by rifampin and isoniazid in treatment of tuberculosis (author's transl)]. ( Abeledo Mezquita, G; Otero Reigada, MC, 1977)
"Analysis of the overt hepatic disease that developed in 114 patients while taking isoniazid for chemoprophylaxis of tuberculosis showed it to be mainly hepatocellular."	3.65	Isoniazid-associated hepatitis in 114 patients. ( Black, M; Epler, GR; Ishak, KG; Mitchell, JR; Zimmerman, HJ, 1975)
" Due to their ability to downregulate many factors (such as cytokines) and activate several enzyme/enzyme systems, herbal substances (such as Gingko biloba extract, curcumin, resveratrol, and silymarin) provide superior protection against harmful mechanisms which induce hepatotoxicity with fewer adverse effects than their synthetic counterparts."	3.54	Drug-induced liver injury and anti-hepatotoxic effect of herbal compounds: a metabolic mechanism perspective. ( Dhull, SB; Kidwai, MK; Rani, J; Rose, PK, 2024)
" However, the occurrence of potentially serious adverse events (AE) is a limitation of TPT regimens."	3.01	A Systematic Review and Meta-Analysis of Tuberculous Preventative Therapy Adverse Events. ( Lisboa Bastos, M; Melnychuk, L; Menzies, D; Perlman-Arrow, S, 2023)
"Isoniazid was associated with higher rates of hepatotoxicity than placebo or rifampin."	3.01	Screening for Latent Tuberculosis Infection in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. ( Asher, GN; Balio, C; Berry, AM; Coffey, CP; Jonas, DE; Kahwati, LC; Lee, LC; Riley, SR; Voisin, CE; Wang, SH; Williams, N, 2023)
"Additionally, treating tuberculosis with antibiotics also poses a serious risk of hepatotoxicity in the patient's body."	3.01	Deciphering the emerging role of phytocompounds: Implications in the management of drug-resistant tuberculosis and ATDs-induced hepatic damage. ( Ahmad, W; Alharbi, JN; Alomary, MN; Alyahya, SA; Ansari, MA; Ansari, SMA; Ather, H; Hani, U; Imran, MA; Islam, N; Jamous, YF; Shoaib, S; Wahab, S, 2023)
" In conclusion, regimen including PZA seems to be safe for late elderly patients with pulmonary TB."	2.90	Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: A prospective randomized open-label study. ( Asaoka, M; Baba, T; Hagiwara, E; Katano, T; Kitamura, H; Komatsu, S; Ogura, T; Okuda, R; Sekine, A; Suido, Y, 2019)
"The main aim of this study is to determine the demographics, compliance, completion rates and adverse events of patients on preventive therapy (PT) for LTBI at our institution."	2.82	Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection. ( Goldberg, HF; Gray, EL, 2016)
"A history of latent tuberculosis infection is not disqualifying for deployment."	2.72	Fatal Isoniazid Hepatotoxicity in the Deployed Environment. ( Cybulski, DJ; White, BK, 2021)
"Pyrazinamide was used in addition to isoniazid and rifampicin in a significantly higher percentage of patients in the ATT-induced hepatitis group (70%) as compared with those in the control group (42%)."	2.68	Antituberculosis treatment-induced hepatotoxicity: role of predictive factors. ( Arora, A; Garg, PK; Pande, JN; Singh, J; Tandon, RK; Thakur, VS, 1995)
" tuberculosis were treated in the initial phase as inpatients for 2-3 months at random with either pyrazinamide (Z) or ethambutol (E) in combination with isoniazid (H) and rifampicin (R)."	2.66	[Which is the best drug combination for the short-term therapy of tuberculosis? A prospective randomized study with 190 patients]. ( Bezel, R; Brändli, O; Häcki, M; Karrer, W; Röthlisberger, K; Rubin, S, 1985)
" In a controlled study of culture-positive advanced pulmonary tuberculosis we have compared treatment regimens with PZA in a dosage of less than 2 g and with ethambutol (EMB)."	2.65	[Pyrazinamide versus ethambutol in short-term therapy of lung tuberculosis. A randomized study]. ( Brändli, O; Fiala, W; Häcki, MA, 1983)
" We aimed to determine whether the INH/RPT-3 regimen had similar or lesser rates of adverse events compared to other LTBI regimens, namely INH for 9 months, INH for 6 months, rifampin for 3 to 4 months, and rifampin plus INH for 3 to 4 months."	2.58	A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection. ( Alvarez, GG; Barbeau, P; Hamel, C; Hutton, B; Pease, C; Skidmore, B; Wolfe, D; Yazdi, F, 2018)
"Treatment of latent tuberculosis infection (LTBI) is an important component of tuberculosis (TB) control, and this study updates a previous network meta-analysis of the best LTBI treatment options to inform public health action and programmatic management of LTBI."	2.55	Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis. ( Beer, N; Harris, RJ; Lipman, MC; Stagg, HR; van der Werf, MJ; Zenner, D, 2017)
" The poor compliance to the treatment of tuberculosis patients due to the adverse events was supposed to be an important factor contributing to the high prevalence."	2.52	Pharmacogenetics of isoniazid-induced hepatotoxicity. ( Atthobari, J; Perwitasari, DA; Wilffert, B, 2015)
"Isoniazid (INH) is an antituberculosis drug associated with idiosyncratic liver injury in susceptible patients."	2.52	Hepatotoxicity mechanisms of isoniazid: A mini-review. ( Guo, HL; Hassan, HM; Luyong, Z; Yousef, BA; Zhenzhou, J, 2015)
"hydrazine) can cause mitochondrial injury, which can lead to mitochondrial oxidant stress and impairment of energy homeostasis."	2.50	Mechanisms of isoniazid-induced idiosyncratic liver injury: emerging role of mitochondrial stress. ( Boelsterli, UA; Lee, KK, 2014)
"Effective treatment of latent tuberculosis infection (LTBI) is an important component of TB elimination programs."	2.50	Treatment of latent tuberculosis infection: a network meta-analysis. ( Abubakar, I; Harris, RJ; Lipman, MC; Muñoz, L; Stagg, HR; Zenner, D, 2014)
" The use of INH for the treatment of LTBI is safe in older patients with clinical or biochemical monitoring."	2.46	Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. ( Khan, KS; Kunst, H, 2010)
"About 97% of patients with pulmonary tuberculosis became bacteriologically quiescent by the 12 months of streptomycin, para-aminosalicylate and isoniazid."	2.41	[Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients]. ( Wada, M, 2001)
"Pyrazinamide, an antituberculous drug discovered in 1952, was first considered as a toxic drug."	2.36	[Toxicity of pyrazinamide in antituberculous treatments (author's transl)]. ( Perdrizet, S; Pretet, S, 1980)
"Isoniazid (INH) is a highly effective single and/or combined first-line anti-tuberculosis (anti-TB) therapy drug, and the hepatotoxicity greatly limits its clinical application."	1.91	Gut microbiota affects sensitivity to immune-mediated isoniazid-induced liver injury. ( Chen, L; Fang, Q; Huang, X; Liu, J; Liu, N; Liu, W; Liu, Y; Ouyang, D; Rao, T; Ye, Z; Zeng, X; Zheng, B, 2023)
"Isoniazid (INH) is a first-line anti-tuberculosis drug which can cause idiosyncratic liver injury, while the underlying mechanisms need to be further elucidated."	1.72	Analysis of time-series gene expression data to explore mechanisms of isoniazid-induced liver toxicity. ( Chu, YP; Huai, C; Li, M; Qin, SY; Tian, ZZ; Zhou, CX; Zhou, W, 2022)
"BACKGROUND Antituberculosis drug-induced hepatotoxicity (ADIH) is a possible adverse event of antitubercular treatment."	1.62	Unusual Recurrence of Antituberculosis Drug-Induced Hepatotoxicity in Children: A Case Series. ( Aliyannissa, A; Febrianti, SA; Nataprawira, HM, 2021)
"Quercetin(Que) has multiple pharmacological properties, and is regarded as a potential protective agent against a variety of organ injuries."	1.56	Quercetin attenuates NLRP3 inflammasome activation and apoptosis to protect INH-induced liver injury via regulating SIRT1 pathway. ( Gao, H; Qu, X; Song, Y; Sun, J; Tao, L; Zhai, J; Zhang, J; Zhang, Y, 2020)
"Isoniazid is an essential drug in the management of tuberculosis but there is a high degree of variation in the Indian population's capacity to acetylate or inactivate isoniazid to the inactive metabolite acetyl isoniazid, and they can be distinctly characterized phenotypically as being either slow or rapid inactivators (the concentration of the enzyme being higher in rapid inactivators)."	1.56	A case series of three patients presenting with isoniazid induced toxicity and N-acetyl transferase 2 gene mutation: A management conundrum for programmatic therapy of tuberculosis in India. ( Darole, P; Munshi, R; Panchal, F; Shetty, P; Sundar, U, 2020)
"Isoniazid (INH) is a first-line anti-tuberculosis drug."	1.51	Mechanism of isoniazid-induced hepatotoxicity in zebrafish larvae: Activation of ROS-mediated ERS, apoptosis and the Nrf2 pathway. ( Cen, J; Chen, XQ; Hsiao, CD; Jia, ZL; Liu, KC; Wang, JB; Wang, RC; Wang, X; Xia, Q; Zhang, F; Zhang, Y, 2019)
"Morphological and metabolic aberrations in the liver caused by long-term use of anti-tubercular agent isoniazid (INH) have been an issue of great concern in tuberculosis treatment."	1.48	Phenolic acid-tethered isoniazid for abrogation of drug-induced hepatotoxicity: design, synthesis, kinetics and pharmacological evaluation. ( Bhilare, NV; Dhaneshwar, SS; Mahadik, KR, 2018)
"High-throughput screening (HTS) of liver toxicants can bridge the gap in understanding adverse effects of chemicals on humans."	1.48	High-throughput toxicity testing of chemicals and mixtures in organotypic multi-cellular cultures of primary human hepatic cells. ( Ehrich, MF; Orbach, SM; Rajagopalan, P, 2018)
"Treatment with lawsone to the RIF-INH administered animals significantly lowered the serum transaminases levels."	1.48	Hepatoprotective effect of lawsone on rifampicin-isoniazid induced hepatotoxicity in in vitro and in vivo models. ( Al-Dhabi, NA; Balakrishna, K; Darvin, SS; Esakkimuthu, S; Ignacimuthu, S; Pandikumar, P; Paulraj, MG; Toppo, E, 2018)
"Isoniazid (INH) is a well-known therapeutic and preventive agent against tuberculosis."	1.48	Isoniazid-induced hepatotoxicity and neurotoxicity in rats investigated by ( Chen, C; Fan, JT; Fu, YH; Hong, W; Jiang, L; Li, MH; Ruan, LY; Wang, JS; Xing, YX; Zhao, H, 2018)
"WHO information note indicates that isoniazid preventive therapy (IPT) is generally safe with little risk of hepatotoxicity."	1.48	Serious hepatotoxicity following use of isoniazid preventive therapy in HIV patients in Eritrea. ( Berhane, A; Debesai, M; Russom, M; Tekeste, T; Teklesenbet, T; Zeregabr, M, 2018)
"Renal transplant candidates (RTC) with latent tuberculosis infection (LTBI) are at significant risk for tuberculosis reactivation."	1.46	Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates. ( Abbo, LM; Camargo, JF; Morris, MI; Rosa, R; Simkins, J, 2017)
"Isoniazid treatment increased serum hepatotoxicity markers (alanine and aspartate transaminase) in young animals but not in old animals, and only reached significance with the high dose in young animals."	1.43	The effect of ageing on isoniazid pharmacokinetics and hepatotoxicity in Fischer 344 rats. ( Cogger, V; de Cabo, R; Hilmer, SN; Huizer-Pajkos, A; Jones, B; Kane, A; Le Couteur, DG; Mach, J; McKenzie, C; Mitchell, SJ; Phillips, L, 2016)
" Monte Carlo simulation was performed with the intent of identifying the probability of achieving an AUC24 greater than the identified threshold of hepatotoxicity with different dosing regimens (2."	1.43	Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB? ( Baraldo, M; Bassetti, M; Cojutti, P; Duranti, S; Isola, M; Pea, F; Viale, P, 2016)
" This study investigate the hepatotoxic potentials of AZT alone, INH alone and AZT+INH treatments and the mitigating potentials of SBN against these drugs induced toxic insults of liver in rats."	1.43	Zidovudine and isoniazid induced liver toxicity and oxidative stress: Evaluation of mitigating properties of silibinin. ( Karthikeyan, S; Raghu, R, 2016)
"Anti-tuberculosis drug-induced hepatotoxicity (ATDH) is a serious adverse reaction to anti-tuberculosis (TB) treatment."	1.43	Association between TXNRD1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a prospective study. ( He, JQ; Ji, GY; Liu, QQ; Sandford, AJ; Wang, Y; Wu, JC; Wu, SQ; Zhang, MM, 2016)
"Isoniazid is a leading cause of liver injury but it is not clear how many cases are reported or how many clinicians and patients adhere to American Thoracic Society (ATS) guidelines."	1.42	Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity. ( Chalasani, NP; Davern, TJ; Fontana, RJ; Gu, J; Hayashi, PH; Hoofnagle, JH; Kleiner, DE; Lee, WM; Navarro, VJ; Stolz, AA; Talwalkar, JA, 2015)
"Co-treatment of isoniazid (INH) and rifampicin (RFP) is well known for clinically apparent liver injury."	1.42	The inhibition of hepatic bile acids transporters Ntcp and Bsep is involved in the pathogenesis of isoniazid/rifampicin-induced hepatotoxicity. ( Deng, Y; Guo, YX; He, LY; Jiang, P; Li, C; Peng, WX; Xu, XF; Zhang, QZ, 2015)
"Coenzyme Q10 was found to effectively reduce the extent of liver damage caused due to INH + RIF."	1.42	The food supplement coenzyme Q10 and suppression of antitubercular drug-induced hepatic injury in rats: the role of antioxidant defence system, anti-inflammatory cytokine IL-10. ( Baskaran, UL; Sabina, EP, 2015)
" A potentially toxic INH dose (120 mg/kg) was injected by i."	1.42	Circadian variation in murine hepatotoxicity to the antituberculosis agent «Isoniazide». ( Aouam, K; Ben-Attia, M; Boughattas, F; Boughattas, NA; Chennoufi, M; Haouas, Z; Maaroufi, K; Miled, A; Reinberg, A; Souayed, N, 2015)
"Isoniazid (INH) can cause serious idiosyncratic liver injury."	1.40	Lack of liver injury in Wistar rats treated with the combination of isoniazid and rifampicin. ( Metushi, IG; Uetrecht, J, 2014)
" Although the use of INH therapy in combination with DMARDs and/or biologics was generally well tolerated, the rate of LFT abnormalities was higher when patients were exposed to INH, and significant abnormalities were more frequent than reported in the INH literature."	1.40	Increased incidence of liver enzymes abnormalities in patients treated with isoniazid in combination with disease modifying and/or biologic agents. ( Arino-Torregrosa, M; Bourré-Tessier, J; Choquette, D, 2014)
"Isoniazide (INH) is a classic antituberculosis drug associated with clinical idiosyncratic drug-induced liver injury."	1.40	Lipopolysaccharide exposure augments isoniazide-induced liver injury. ( Chen, M; Jiang, Z; Su, Y; Sun, L; Wang, T; Zhang, L; Zhang, Y, 2014)
" Moreover, the rs1495741 genotypes showed an association with the isoniazid dosage required for induction of hepatotoxicity."	1.39	The NAT2 tag SNP rs1495741 correlates with the susceptibility of antituberculosis drug-induced hepatotoxicity. ( Ho, HT; Hsiong, CH; Hu, OY; Huang, TY; Jong, YJ; Lu, PL; Perng, WC; Wang, NC; Wang, TH, 2013)
"Isoniazid (INH) is an antituberculosis drug that has been associated with idiosyncratic liver injury in susceptible patients."	1.39	Isoniazid-induced cell death is precipitated by underlying mitochondrial complex I dysfunction in mouse hepatocytes. ( Alder, NN; Boelsterli, UA; Fujimoto, K; Krueger, W; Lee, KK; Pinkert, CA; Rasmussen, T; Schwall, CT; Zhang, C, 2013)
" Single dose (25 mg/kg BW) oral pharmacokinetic studies were performed in plasma and various tissues of rats."	1.39	Pharmacokinetics, tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticles. ( Bhandari, R; Kaur, IP, 2013)
"Large-scale screening for NAT2 and CYP2E1 genotypes can prove useful in predicting the risk of adverse effects."	1.39	N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients. ( Callegari-Jacques, SM; de Carvalho, DC; Fernandes, DC; Hutz, MH; Ribeiro Dos Santos, AK; Santos, NP; Santos, SE; Silva, CA; Vallinoto, AC, 2013)
"Tuberculosis (TB) treatment can cause serious sequelae including adverse effects such as anti-TB drug-induced hepatotoxicity (ATDH)."	1.38	Genetic variants in antioxidant pathway: risk factors for hepatotoxicity in tuberculosis patients. ( Fukushima, K; Higuchi, N; Inamine, T; Kohno, S; Kondo, S; Mawatari, T; Nakaura, A; Nanashima, K; Suyama, N; Tahara, N; Tsukamoto, K; Yanagihara, K, 2012)
"Rifampicin together with rifampicin and metabolites of isoniazid produce cellular toxic effects and hydrazine may be the most toxiferous metabolite."	1.38	Cellular toxicity of isoniazid together with rifampicin and the metabolites of isoniazid on QSG-7701 hepatocytes. ( Hou, YN; Tang, JH; Wu, HH; Zhan, ZL; Zhang, XL; Zhang, ZH, 2012)
"Pyrazinamide was omitted in 15 cases while rifampicin only in one patient."	1.38	Management of and risk factors related to hepatotoxicity during tuberculosis treatment. ( Ağca, S; Arda, H; Babalık, A; Bakırcı, N; Calışır, HC; Cetintaş, G; Kızıltaş, S; Oruç, K, 2012)
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."	1.37	FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011)
"A 54-year-old woman was admitted for pleural tuberculosis diagnosed by right chest pain and cough."	1.37	A case of isoniazid-induced liver injury diagnosed by use of the DLST, and successful reintroduction of isoniazid for pleural tuberculosis. ( Fujita, M; Ikegame, S; Kajiki, A; Nakanishi, Y; Wakamatsu, K, 2011)
"The indications for treatment for latent tuberculosis infection were revised in 2007 to reflect that any subject with a higher risk of tuberculosis regardless of age should be treated."	1.37	[Liver dysfunction during treatment of latent tuberculosis infection]. ( Nakazono, T; Shimao, T; Sugita, H; Tagawa, H; Takase, A; Takayanagi, K; Tezuka, N; Yamaguchi, T, 2011)
" 30 male SD rats were allocated randomly into two groups, a control group and an isoniazid group, and treated, respectively, with pure water and isoniazid at low dosage (10 mg/(kg day)) for 42 days by oral gavage."	1.37	DNA methylation in the rat livers induced by low dosage isoniazid treatment. ( Chen, Y; Feng, F; Hao, J; Huang, X; Shen, L; Sun, S; Zhang, B; Zu, X, 2011)
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."	1.36	Developing structure-activity relationships for the prediction of hepatotoxicity. ( Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010)
"Toxic agents were mushroom poisoning (n = 2), Datura stramonium (n = 1), yellow phosphorous (n = 1) and INH (n = 1)."	1.35	Liver transplantation for acute liver failure due to toxic agent ingestion in children. ( Akman, SA; Arikan, C; Aydogdu, S; Baran, M; Cakir, M; Kilic, M; Saz, EU; Saz, UE; Tumgor, G; Yuksekkaya, HA; Zeytunlu, M, 2009)
"Liver diseases are common in patients with HIV due to viral hepatitis B and C co-infections, opportunistic infections or malignancies, antiretroviral drugs and drugs for opportunistic infections."	1.35	The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. ( Colebunders, R; Feld, J; Kambugu, A; Katabira, E; Katwere, M; Ocama, P; Opio, KC; Piloya, T; Ronald, A; Thomas, D, 2008)
"A case of acute respiratory failure due to diaphragmatic weakness following adalimumab therapy for psoriasis is described."	1.35	Acute bilateral phrenic neuropathy following treatment with adalimumab. ( Alexopoulou, A; Antoniou, C; Archimandritis, A; Katsambas, A; Katsaounis, P; Kilidireas, K; Koskinas, J; Papageorgiou, C; Soultati, A, 2009)
"Isoniazid is a widely used drug for the treatment of tuberculosis, but hepatotoxicity is a major concern during treatment."	1.35	Protective effects of thiopronin against isoniazid-induced hepatotoxicity in rats. ( Chen, J; Dong, G; He, C; Liu, Y; Peng, R; Yue, J, 2009)
" Metabolism and the formation of toxic metabolites of the TB drugs may play an important role in the development of ATDH."	1.35	Isoniazid and its toxic metabolite hydrazine induce in vitro pyrazinamide toxicity. ( Aarnoutse, RE; Boeree, MJ; Dekhuijzen, PN; Peters, WH; Roelofs, HM; Tostmann, A; van der Ven, AJ, 2008)
" Although severe isoniazid hepatotoxicity is very uncommon in children, this case emphasizes the need to limit skin testing to persons who have a risk factor for infection and to educate parents on how to monitor for adverse effects during treatment."	1.35	Unintended consequences: mandatory tuberculin skin testing and severe isoniazid hepatotoxicity. ( Jereb, JA; Lobato, MN; Starke, JR, 2008)
"Hepatotoxicity was revealed by traditional toxicity evaluation in rats treated with higher dosage and longer treatment of INH."	1.34	[Metabonomics profile of urine from rats administrated with different treatment period of isoniazid]. ( Liao, Y; Peng, SQ; Yan, XZ; Zhang, LS, 2007)
"To study the frequency and degree of adverse effect, other than liver dysfunction, of isoniazid (INH) preventive therapy in Japanese people."	1.34	[Adverse effect other than liver dysfunction in treatment of latent tuberculous infection by isoniazid]. ( Hoshino, H; Ito, K; Kato, S; Masuyama, H; Nakazono, T; Sugita, H; Yoshiyama, T, 2007)
"Major adverse reactions to antituberculosis drugs can cause significant morbidity, and compromise treatment regimens for tuberculosis (TB)."	1.32	Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. ( Menzies, D; Parisien, I; Pelletier, M; Rocher, I; Valiquette, C; Yee, D, 2003)
"Isoniazid is an efficacious treatment for latent tuberculosis."	1.32	Use of isoniazid for latent tuberculosis infection in a public health clinic. ( LoBue, PA; Moser, KS, 2003)
"To improve the bioavailability of antitubercular drugs (ATDs) as well as to assess the feasibility of administering ATDs via the respiratory route, this study reports the formulation of three frontline ATDs, i."	1.32	Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. ( Khuller, GK; Pandey, R; Prasad, B; Sharma, A; Sharma, S; Zahoor, A, 2003)
" Thereafter, two groups of 15 male Sprague-Dawley rats each were treated with the toxic dose of paracetamol intraperitoneally to induce severe hepatotoxicity."	1.32	The role of cytochrome-P450 inhibitors in the prevention of hepatotoxicity after paracetamol overdose in rats. ( Abraham, AM; Barr, S; Coetsee, C; Walubo, A, 2004)
"2% developed adverse hepatic reaction within the first month of INH + RMP treatment."	1.31	Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. ( Azuma, J; Fukuda, T; Igarashi, T; Ito, M; Komuta, K; Maeda, K; Maekura, R; Ogura, T; Ohno, M; Yamaguchi, I; Yamamoto, I; Yamamoto, Y; Yokota, S, 2000)
"Hydrocephalus was common (28 of 41 tested), but only 8 (15."	1.31	[Central nervous system tuberculosis in children: 2. Treatment and outcome]. ( Gusmão Filho, FA; Marques, HH; Marques-Dias, MJ; Ramos, SR, 2001)
"She presented repetitive generalized convulsions with metabolic acidosis, treated with diazepam and 7."	1.31	[Acute isoniazid poisoning presenting convulsion and liver dysfunction]. ( Hamabe, Y; Kiyota, K, 2001)
"Tuberculosis is a common infection of renal transplant recipients in developing countries."	1.30	Tuberculosis after renal transplantation: experience of one Turkish centre. ( Ark, E; Beşişik, F; Ecder, T; Ece, T; Kiliçarslan, I; Sever, MS; Tabak, L; Türkmen, A; Yildiz, A, 1998)
"Out of 1128 new pulmonary tuberculosis patients, six-hundred twenty started treatment with six-month (2HRZS or E/4HRE) in Fukujuji Hospital, JATA, in Tokyo from January 1991 to December 1996."	1.30	[Six-months chemotherapy (2HRZS or E/4HRE) of new cases of pulmonary tuberculosis--six year experiences on its effectiveness, toxicity, and acceptability]. ( Ito, K; Mizutani, S; Ogata, H; Sugita, H; Wada, M; Yoshiyama, T, 1999)
"Pyrazinamide appeared to increase the hepatotoxicity of isoniazid and rifampicin."	1.29	Anti tubercular treatment induced hepatotoxicity: does acetylator status matter? ( Garg, PK; Singh, J; Tandon, RK; Thakur, VS, 1995)
"Acetone pretreatment reduced the inhibition of protein synthesis caused by hydrazine compared to the control."	1.29	Role of cytochrome P450 in hydrazine toxicity in isolated hepatocytes in vitro. ( Delaney, J; Timbrell, JA, 1995)
"Four patients presented hepatic encephalopathy."	1.29	[Severe hepatotoxicity of tuberculostatic agents. Increase in the incidence]. ( Bruguera, M; Mas, A; Moitinho, E; Rodés, J; Salmerón, JM, 1996)
"Twenty-nine patients with extensive pulmonary tuberculosis and drug-induced hepatitis were treated with ofloxacin along with other relatively non-hepatotoxic drugs, either during the interim phase to await recovery of liver function in some, or as definitive therapy as required by the compromised hepatic status of others."	1.28	Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction. ( Kwan, SY; Lee, J; Wong, PC; Yew, WW, 1992)
" The results suggested that the pharmacokinetic behavior of Iso in rats belonged to a 2-compartment model."	1.28	Effects of rifampicin on pharmacokinetics of isoniazid and its metabolite acetylhydrazine in rats. ( Cheng, WB; Li, D; Wang, ZY; Zhang, RL, 1992)
"The decision was analyzed for an intravenous drug abuser who may have been anergic, while tuberculin test status, race, and gender were varied."	1.28	Isoniazid as preventive therapy in HIV-infected intravenous drug abusers. A decision analysis. ( Jordan, TJ; Lewit, EM; Montgomery, RL; Reichman, LB, 1991)
"In Zimbabwe patients with pulmonary tuberculosis who are acid-fast bacilli (AFB) negative in the sputum are treated in the two month intensive phase with isoniazid, thiacetazone pyrazinamide and streptomycin (regimen A)."	1.28	Effects of two pulmonary tuberculosis drug treatments and acetylator status on liver function in a Zimbabwean population. ( Kusema, T; Mhonda, M; Neill, P; Nhachi, CF; Pringle, D, 1990)
"We investigated the pharmacokinetic interaction of RMP (administered from the first day of treatment onwards), PZA (given from the second day onwards), and INH (day 17 onwards) in ten, previously untreated patients with pulmonary tuberculosis (five slow acetylators and five fast acetylators)."	1.28	[Clinico-pharmacokinetic interactions of rifampicin, pyrazinamide and isoniazide]. ( Loos, U; Musch, E; Schwabe, HK, 1990)
"Isoniazid (INH) is a selective inducer of cytochrome P-450 isozymes that are involved in the biotransformation of organohalogen anesthetics."	1.28	Isoniazid potentiation of a guinea pig model of halothane-associated hepatotoxicity. ( Gandolfi, AJ; Hall, PM; Lind, RC, 1990)
" The main factors increasing the risk of hepatic toxicity was a high dosage of INH and overall malnutrition."	1.28	[Hepatotoxicity of the combination of isoniazid-rifampicin in African children. Role of malnutrition and HB virus]. ( Boguikouma, JB; Gahouma, D; Gendrel, D; Mouba, JF; Moussavou, A; Nardou, M, 1989)
"When pyrazinamide was used in combination with isoniazid or rifampicin a marked increase in the activity of aspartate and alanine aminotransferases in blood serum and induction of lipid peroxidation in the liver were observed in addition to the disorders in cholopoiesis and lowering of the reduced glutathion levels."	1.28	[Hepatotoxic effect of a combination of pyrazinamide with isoniazid and rifampicin]. ( Klimniuk, EV; Slivka, IuI; Tabachuk, OE, 1989)
"Possible toxic side-effects of antituberculous chemotherapy are studied in 718 children affected with pulmonary tuberculosis."	1.27	[Toxicity in the current treatment of pulmonary tuberculosis in children]. ( Alcáide Megías, J; Altet Gómez, MN; Boque Genovard, MA, 1984)
" As a consequence there are no grounds for reducing the dosage of isoniazid given to patients with impaired renal function."	1.27	[The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis]. ( Ellard, GA, 1984)
" Major toxic effects occurred in 22 patients; in 14 during the daily phase and in 8 during the twice-weekly phase."	1.27	Undesirable side effects of isoniazid and rifampin in largely twice-weekly short-course chemotherapy for tuberculosis. ( Dutt, AK; Moers, D; Stead, WW, 1983)
" The dosage used according to this protocol varied greatly, going from 1."	1.27	[Value of determining plasma INH during antitubercular treatment. Retrospective analysis of 204 cases]. ( Cheminat, JC; Ducarrouge, C; Lavarenne, J; Molina, C; Paire, M, 1983)
"Isoniazid was discontinued and later readministered in gradually increasing intrathecal and subsequently oral doses, up to the final dose of 400 mg/day."	1.27	Hepatitis on high dose isoniazid: reintroduction of the drug in severe tuberculous meningitis. ( Constantoulakis, M; Daikos, GK; Danielides, IC, 1983)
" Minor adverse reactions occurred with similar frequencies during daily (5%) and intermittent (5%) treatment but in no case was modification of rifampicin dosage required."	1.27	Safety of thrice-weekly rifampicin for tuberculosis in South-East Asian refugees. ( McKenzie, DK; Mukerjee, CM, 1985)
" Toxic doses of acetylisoniazid and acetylhydrazine, radiolabeled in the acetyl group, were found to bind covalently to liver protein in vivo."	1.26	Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo. ( Mitchell, JR; Nelson, SD; Snodgrass, WR; Timbrell, JA, 1980)
"Although there was an excess of alcohol abusers in the LTT-positive group, the probability of developing liver dysfunction amongst alcohol abusers in that group was twice as great as for LTT-negative alcohol abusers."	1.26	The predictive value of the lymphocyte transformation test in isoniazid-associated hepatitis. ( McPhilips-Feener, S; Rutherford, WJ; Warrington, RJ, 1982)
" The overall effect of isoniazid in vivo was to increase metabolism of acetylhydrazine through the microsomal pathway leading to increased covalent binding of the toxic reactive intermediate to liver protein."	1.26	Studies on the role of acetylhydrazine in isoniazid hepatotoxicity. ( Timbrell, JA, 1979)
" Uniform practice was found with regard to the dosage of isoniazid administered, duration of treatment, and most other indications for preventive therapy recommended by the American Thoracic Society and the U."	1.26	Tuberculosis chemoprophylaxis practices in metropolitan clinics. ( Brewin, A; Gibert, J; Herskowitz, D; Leff, A, 1979)
"3."	1.25	Exchange transfusion in hepatic coma: factors affecting results, with long-term follow-up data. ( Darin, JC; Hussey, CV; Lewis, JD; Varma, RR, 1975)

Research

Studies (790)

Authors

Clinical Trials (17)

Trial Overview

Trial Outcomes

Cumulative Incidence of Participants Experiencing a Grade 3/4 Hepatotoxicity

Timeframe	Studies, this research(%)	All Research%
pre-1990	364 (46.08)	18.7374
1990's	90 (11.39)	18.2507
2000's	86 (10.89)	29.6817
2010's	194 (24.56)	24.3611
2020's	56 (7.09)	2.80

Authors	Studies
Fourches, D	1
Barnes, JC	1
Day, NC	1
Bradley, P	1
Reed, JZ	1
Tropsha, A	1
Greene, N	1
Fisk, L	1
Naven, RT	1
Note, RR	1
Patel, ML	1
Pelletier, DJ	1
Morgan, RE	2
Trauner, M	1
van Staden, CJ	2
Lee, PH	1
Ramachandran, B	1
Eschenberg, M	1
Afshari, CA	2
Qualls, CW	1
Lightfoot-Dunn, R	1
Hamadeh, HK	2
Ekins, S	1
Williams, AJ	1
Xu, JJ	1
Chen, M	3
Vijay, V	1
Shi, Q	2
Liu, Z	2
Fang, H	2
Tong, W	3
Dawson, S	1
Stahl, S	2
Paul, N	1
Barber, J	1
Kenna, JG	2
Ding, D	1
Kelly, R	1
Sakatis, MZ	1
Reese, MJ	2
Harrell, AW	1
Taylor, MA	1
Baines, IA	1
Chen, L	3
Bloomer, JC	1
Yang, EY	1
Ellens, HM	1
Ambroso, JL	1
Lovatt, CA	1
Ayrton, AD	1
Clarke, SE	1
Warner, DJ	1
Chen, H	1
Cantin, LD	1
Walker, CL	1
Noeske, T	1
Chen, Y	2
Kalyanaraman, N	1
Kalanzi, J	1
Dunn, RT	1
Suzuki, A	2
Thakkar, S	1
Yu, K	1
Hu, C	1
Cheng, X	2
Zhu, JL	1
Li, Y	10
Luo, WW	2
Xiang, HR	2
Zhang, QZ	3
Peng, WX	3
Ben Said, D	1
Dahmani, I	1
Ben Ali, R	1
Bassem, H	1
El Fekih, M	1
Chedly, A	1
Elmay, MV	1
Gaies, E	1
El Aidli, S	1
Tseng, SY	1
Huang, YS	4
Chang, TE	1
Perng, CL	1
Huang, YH	1
He, B	1
Yang, S	1
Guo, JQ	1
Yan, XF	1
Tang, S	1
Buabeid, MA	1
Arafa, EA	1
Rani, T	1
Ahmad, FUD	1
Ahmed, H	1
Hassan, W	1
Murtaza, G	1
Tian, ZZ	1
Zhou, CX	1
Zhou, W	1
Li, M	1
Chu, YP	1
Huai, C	1
Qin, SY	1
Wang, X	4
Zhao, J	4
Zhang, R	2
Liu, X	4
Ma, C	2
Cao, G	1
Wei, Y	4
Yang, P	1
Wen, Y	2
Zhang, G	6
Wu, X	4
Yang, J	4
Li, G	1
Bao, X	1
Suo, Y	1
Xu, H	1
Deng, Y	3
Feng, T	1
Deng, G	1
Song, Y	5
Qu, X	3
Tao, L	3
Gao, H	3
Zhang, Y	10
Zhai, J	3
Gong, J	1
Hu, T	1
Daly, AK	5
Liu, N	1
Liu, J	2
Zheng, B	1
Zeng, X	1
Ye, Z	2
Huang, X	2
Liu, W	2
Liu, Y	3
Fang, Q	1
Rao, T	1
Ouyang, D	1
Sun, Y	2
Ma, N	1
Cai, S	1
Qin, L	1
Huang, CH	1
Liu, CQ	1
Zhao, CF	1
Li, PL	1
Tang, TS	1
Li, J	2
Xie, LN	1
Shao, B	1
Shao, J	1
Mao, L	1
Li, R	1
Zhang, L	3
Zhu, BZ	1
Melnychuk, L	1
Perlman-Arrow, S	1
Lisboa Bastos, M	1
Menzies, D	6
Jonas, DE	1
Riley, SR	1
Lee, LC	1
Coffey, CP	1
Wang, SH	1
Asher, GN	1
Berry, AM	1
Williams, N	1
Balio, C	1
Voisin, CE	1
Kahwati, LC	1
Ezhilarasan, D	1
Bakshi, S	1
Kaur, M	1
Verma, A	2
Sharma, S	3
Zhu, W	1
Su, H	1
Huang, Y	1
Chen, S	2
Shi, Y	1
Long, Y	1
Qiu, Y	1
Wei, J	1
Li, T	1
Yang, C	1
Cao, H	1
Mo, S	1
Li, B	3
Huang, Z	1
Wu, J	2
Zhang, K	1
Gao, Y	1
Ansari, MA	1
Shoaib, S	1
Alomary, MN	1
Ather, H	1
Ansari, SMA	1
Hani, U	1
Jamous, YF	1
Alyahya, SA	1
Alharbi, JN	1
Imran, MA	1
Wahab, S	1
Ahmad, W	1
Islam, N	1
Ma, Y	2
Li, Q	1
Zhang, H	3
Fu, S	1
Li, H	1
Li, S	1
Hou, P	1
Rani, J	1
Dhull, SB	1
Rose, PK	1
Kidwai, MK	1
Baumann, L	1
Holbech, H	1
Schmidt-Posthaus, H	1
Moissl, AP	1
Hennies, M	1
Tiedemann, J	1
Weltje, L	1
Segner, H	1
Braunbeck, T	1
Bai, H	1
Wu, T	1
Jiao, L	1
Wu, Q	1
Zhao, Z	1
Song, J	3
Liu, T	1
Lv, Y	1
Lu, X	1
Ying, B	1
Yuliwulandari, R	1
Prayuni, K	1
Susilowati, RW	1
M Sofro, AS	1
Tokunaga, K	2
Shin, JG	1
He, X	1
Wang, L	2
Xu, J	3
Cho, T	2
Uetrecht, J	8
Fromenty, B	1
Ronald, LA	1
FitzGerald, JM	3
Bartlett-Esquilant, G	1
Schwartzman, K	4
Benedetti, A	2
Boivin, JF	1
Fasbender, F	1
Obholzer, M	1
Metzler, S	1
Stöber, R	1
Hengstler, JG	1
Watzl, C	1
Zhao, H	2
Wang, Y	4
Zhang, T	1
Wang, Q	3
Xie, W	1
Chung, SJ	1
Lee, H	1
Koo, GW	1
Min, JH	1
Yeo, Y	1
Park, DW	1
Park, TS	1
Moon, JY	1
Kim, SH	4
Kim, TH	1
Sohn, JW	1
Yoon, HJ	1
Liu, F	1
Jiang, FB	1
Li, YT	1
Liu, RM	1
Wu, ZY	1
Yan, CW	1
Liu, L	2
Li, X	1
Huang, C	2
Bian, Y	2
Cao, J	3
Qu, W	1
Miao, L	2
Goh, ZH	1
Tee, JK	1
Ho, HK	1
Sun, J	1
Zhang, J	3
Brewer, CT	1
Kodali, K	1
Shaw, TI	1
Peng, J	1
Chen, T	1
Rao, Z	2
Bourhia, M	1
Ullah, R	1
S Alqahtani, A	1
Ibenmoussa, S	1
Chiang, LY	1
Baumann, B	1
Romanowski, K	1
Kumar, D	1
Campbell, JR	1
Djurdjev, O	1
Morshed, M	1
Sekirov, I	1
Cook, VJ	3
Levin, A	1
Johnston, JC	1
Shetty, P	1
Panchal, F	1
Munshi, R	1
Sundar, U	1
Darole, P	1
Ahmad, E	1
Jahangir, M	1
Akhtar, ZM	1
Ishtiaq, S	1
Mukhtar, H	1
Haider, HMF	1
Bukhari, NI	1
Xu, N	1
Yang, JX	1
Pan, Y	1
Tang, P	1
Song, Q	1
Zhu, L	3
Ma, S	1
Cybulski, DJ	1
White, BK	1
Nicoletti, P	1
Devarbhavi, H	1
Goel, A	1
Venkatesan, R	1
Eapen, CE	1
Grove, JI	1
Zafer, S	1
Bjornsson, E	1
Lucena, MI	1
Andrade, RJ	2
Pirmohamed, M	2
Wadelius, M	1
Larrey, D	1
Maitland-van der Zee, AH	1
Ibanez, L	1
Watkins, PB	3
Aithal, GP	2
Sharma, V	1
Kaur, R	1
Sharma, VL	1
Sanjay, S	2
Girish, C	2
Toi, PC	2
Bobby, Z	2
Naji, KM	1
Al-Khatib, BY	1
Al-Haj, NS	1
D'souza, MR	1
Nataprawira, HM	1
Aliyannissa, A	1
Febrianti, SA	1
Fan, X	1
Ren, T	1
Yang, W	1
Zhang, X	1
Yuan, L	1
Singh, DK	1
Tousif, S	1
Bhaskar, A	1
Devi, A	1
Negi, K	1
Moitra, B	1
Ranganathan, A	1
Dwivedi, VP	1
Das, G	1
Xiang, X	1
Wu, SQ	3
Chen, G	2
Zhang, MM	3
Wang, MG	1
Wang, FJ	1
Sandford, AJ	2
He, JQ	3
Momose, M	1
Asahina, A	1
Hayashi, M	1
Yanaba, K	1
Umezawa, Y	1
Nakagawa, H	1
Ogese, MO	1
Faulkner, L	2
Jenkins, RE	1
French, NS	2
Copple, IM	1
Antoine, DJ	1
Elmasry, M	1
Malik, H	1
Goldring, CE	1
Park, BK	2
Betts, CJ	1
Naisbitt, DJ	3
Urfi, MK	1
Mujahid, M	3
Rahman, MA	4
Ogihara, T	1
Arakawa, H	1
Jomura, T	1
Idota, Y	1
Koyama, S	1
Yano, K	1
Kojima, H	1
Zenner, D	2
Beer, N	1
Harris, RJ	2
Lipman, MC	2
Stagg, HR	2
van der Werf, MJ	1
Feng, M	1
Wu, JC	5
Ji, GY	2
Liu, QQ	2
Chan, SL	1
Chua, APG	1
Aminkeng, F	1
Chee, CBE	1
Jin, S	1
Loh, M	1
Gan, SH	1
Wang, YT	1
Brunham, LR	1
Lee, M	1
Rees, CA	1
Munden, MM	1
Zheng, G	2
Wang, J	6
Mu, S	1
Ren, Q	2
Feng, F	3
Mawarti, H	1
Rajin, M	1
Asumta, Z	1
Ngongondo, M	1
Miyahara, S	1
Hughes, MD	1
Sun, X	1
Bisson, GP	1
Gupta, A	1
Kumwenda, J	1
Lavenberg, JA	1
Torres, TS	1
Nyirenda, M	1
Kidonge, KK	1
Hosseinipour, MC	1
Mi, Y	1
Shi, C	1
Tersigni, C	1
Venturini, E	1
Cordola, C	1
Piccini, P	1
Bianchi, L	2
Montagnani, C	1
Sollai, S	1
Chiappini, E	1
de Martino, M	1
Galli, L	1
Bhilare, NV	1
Dhaneshwar, SS	1
Mahadik, KR	1
Han, T	1
Sun, S	2
Pease, C	1
Hutton, B	1
Yazdi, F	1
Wolfe, D	1
Hamel, C	1
Barbeau, P	1
Skidmore, B	1
Alvarez, GG	1
Atwine, D	1
Bonnet, M	1
Taburet, AM	1
Orbach, SM	1
Ehrich, MF	1
Rajagopalan, P	1
Nwidu, LL	2
Teme, RE	1
Darvin, SS	1
Esakkimuthu, S	1
Toppo, E	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Multi-Center Trial to Study Acute Liver Failure in Adults[NCT00518440]		3,488 participants (Actual)	Observational	1998-01-31	Completed
A Randomized, Four-arm Open Label Phase Two-b Clinical Trial to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of High Dose Rifampicin in TB-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy[NCT03982277]	Phase 2	130 participants (Actual)	Interventional	2019-04-30	Completed
Estimation of Plasma Free and Total Drug Levels of Rifampicin, Isoniazid and Pyrazinamide in Patients on Antituberculosis Therapy and Its Correlation With Development of Drug Induced Hepatotoxicity[NCT01456845]		110 participants (Actual)	Observational	2010-08-31	Completed
One-month Latent Tuberculosis Treatment for Renal Transplant Candidates[NCT05411744]	Phase 4	25 participants (Anticipated)	Interventional	2022-07-01	Recruiting
A Randomized, Placebo-Controlled Study of Limited vs. Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana[NCT00164281]	Phase 4	2,000 participants (Actual)	Interventional	2004-11-30	Completed
URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence[NCT03302299]	Phase 4	302 participants (Actual)	Interventional	2017-04-07	Completed
Efficacy of Risk-Targeted Video Based Directly on Observed Therapy for Latent TB[NCT03783728]		0 participants (Actual)	Observational	2019-06-30	Withdrawn (stopped due to Investigator is leaving the University)
A Phase II Trial to Describe the Pharmacokinetics, Safety and Efficacy of Pharmacogenetics-guided Dosing of Isoniazid in Patients With HIV-associated TB[NCT05124678]	Phase 2	40 participants (Anticipated)	Interventional	2021-12-07	Recruiting
Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Antituberculosis Treatment Induced Hepatotoxicity[NCT00405301]	Phase 4	175 participants (Actual)	Interventional	2006-12-31	Completed
A Randomized Double Blind Placebo Controlled Trial of Adjunctive Dexamethasone for the Treatment of HIV-infected Adults With Tuberculous Meningitis[NCT03092817]	Phase 3	520 participants (Actual)	Interventional	2017-05-25	Active, not recruiting
A Randomized Double Blind Placebo Controlled Non-inferiority Trial of Adjunctive Dexamethasone for the Treatment of HIV-uninfected Adults With Tuberculous Meningitis Stratified by Leukotriene A4 Hydrolase Genotype[NCT03100786]	Phase 3	640 participants (Anticipated)	Interventional	2018-02-08	Recruiting
[NCT00298870]	Phase 4	172 participants (Actual)	Interventional	2005-06-30	Completed
Prophylactic Use of Entecavir to Reduce Hepatitis Flare in Highly Viremic HBV Patients With Active Tuberculosis Receiving Anti-tuberculous Treatment[NCT01724723]	Phase 4	50 participants (Anticipated)	Interventional	2012-12-31	Not yet recruiting
Rifampin to Reduce Elevated Levels of Blood and Urine Calcium in Patients With Idiopathic Infantile Hypercalcemia[NCT03384121]	Phase 1	5 participants (Anticipated)	Interventional	2018-02-22	Recruiting
The Importance of Exogenous Reinfection in the Tuberculosis Endemic of Taiwan[NCT00173433]		150 participants (Anticipated)	Observational	2005-08-31	Completed
Primary Prophylaxis for Prevention of TB in Prison's Populations[NCT03028129]	Phase 4	467 participants (Actual)	Interventional	2017-09-04	Terminated (stopped due to Interim analysis showed efficacy less than 2.5%.)
Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis in the Kilimanjaro Region, Tanzania.[NCT00760149]	Phase 2	150 participants (Actual)	Interventional	2010-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Safety will be assessed by the occurrence of a Grade 3/4 hepatotoxicity at any time during the assigned treatment period. (NCT03302299)
Timeframe: Hepatotoxicity occurring during the six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.

Number of Participants Who Discontinued Treatment

Intervention	percent (Number)
INH and Vitamin B6	8.3

Lack of tolerability will be defined as any isoniazid (INH) treatment discontinuation prior to completion of the prescribed course (6 months of INH taken over a maximum period of 9 months) due to side effects or alanine transaminase (ALT)/aspartate transaminase (AST) elevations. (NCT03302299)
Timeframe: Six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.

Number of Participants With Alanine Transaminase (ALT) or Aspartate Transaminase (AST) Elevations at Study Screening

Intervention	Participants (Count of Participants)
INH and Vitamin B6	32

Alanine transaminase (ALT) or aspartate transaminase (AST) elevations (>2x the upper limit of normal) at study screening (NCT03302299)
Timeframe: Study screening visit

Number of Participants With Latent Tuberculosis at Study Screening.

Intervention	Participants (Count of Participants)
Study Screening	80

Latent tuberculosis assessed at screening via tuberculin skin testing (TST). A TST induration >=5mm was considered positive for latent tuberculosis. (NCT03302299)
Timeframe: Study screening visit

INH Concentration in Hair: (INH Pmol + Acetyl INH Pmol) Per mg of Hair

Intervention	Participants (Count of Participants)
Study Screening	308

INH concentration in hair (pmol/mg) will be measured at 3- and 6- months during INH therapy. (NCT03302299)
Timeframe: Measured at 3- and 6- months after INH initiation

Percentage of Participants With Suboptimal INH Medication Adherence

Intervention	pmol/mg (Median)
	at 3 months	at 6 months
INH and Vitamin B6	36.0	37.8

Suboptimal INH adherence was defined as <90% of days with at least 1 electronic medication management (EMM) pill cap opening in the previous 90 days, at 3- and 6-months. (NCT03302299)
Timeframe: Adherence will be measured over the 6 months on INH or until INH discontinuation (whichever is shorter)

Self-reported INH Medication Adherence: Number of Days Taking INH in the Past 30 Days

Intervention	percentage of participants (Number)
	at 3 months	at 6 months
INH and Vitamin B6	31.3	43.9

"Participants were asked In the past 30 days, how many days in total have you not taken your pill? and were presented with a visual analog scale (VAS) to indicate the percentage of INH taken in the past 30 days. We converted the VAS percentage into number of days out of 30 to match the first question. Our final self-report measure was the minimum number of the 2 self-reported measurements." (NCT03302299)
Timeframe: Self-reported INH medication adherence via VAS will be measured 3- and 6- months after starting INH

Self-reported INH Medication Adherence by the Self Rating Single Item (SRSI) Scale

Intervention	days (Median)
	at 3 months	at 6 months
INH and Vitamin B6	30	30

The Self Rating Single Item (SRSI) adherence scale asks participants to rate their ability to take their medications as prescribed over the past 30 days. Participants reporting INH use in the prior 30 days at the 3- or 6-month interview are included here, and reported their INH adherence in the prior 30 days as excellent, very good, good, fair, poor, or very poor. (NCT03302299)
Timeframe: Self-reported INH medication adherence via SRSI will be measured 3- and 6- months after starting INH

Quantiferon TB Gold Plus (QIAGEN®) Conversion at the Premature Exclusion Visit.

Intervention	Participants (Count of Participants)
	At 3 months72558043	At 6 months72558043
	Excellent	Very good	Good	Fair	Poor	Very poor
INH and Vitamin B6	160
INH and Vitamin B6	79
INH and Vitamin B6	38
INH and Vitamin B6	2
INH and Vitamin B6	124
INH and Vitamin B6	90
INH and Vitamin B6	41
INH and Vitamin B6	4
INH and Vitamin B6	0
INH and Vitamin B6	1

Number of participants who had a Quantiferon TB Gold Plus (QIAGEN®) score greater than or equal to 0.35 international units per milliliter, at the time of the premature exclusion visit, on all participants in the group. (NCT03028129)
Timeframe: up to 6 months

Reviews

Trials

Other Studies

655 other studies available for isoniazid and Chemical and Drug Induced Liver Injury

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Pr	2016
Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis. Journal of the Chinese Medical Association : JCMA, 2021, 11-01, Volume: 84, Issue:11 Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Latent Tube	2021
Genetics of drug-induced liver injury: Current knowledge and future prospects. Clinical and translational science, 2023, Volume: 16, Issue:1 Topics: Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Genotype; H	2023
A Systematic Review and Meta-Analysis of Tuberculous Preventative Therapy Adverse Events. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 07-26, Volume: 77, Issue:2 Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Drug Therapy, Combinati	2023
Screening for Latent Tuberculosis Infection in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA, 2023, 05-02, Volume: 329, Issue:17 Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Latent Tube	2023
Antitubercular drugs induced liver injury: an updated insight into molecular mechanisms. Drug metabolism reviews, 2023, Volume: 55, Issue:3 Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liver Injur	2023
Deciphering the emerging role of phytocompounds: Implications in the management of drug-resistant tuberculosis and ATDs-induced hepatic damage. Journal of infection and public health, 2023, Volume: 16, Issue:9 Topics: Antitubercular Agents; Bacterial Proteins; Chemical and Drug Induced Liver Injury; Drug Resistance,	2023
Drug-induced liver injury and anti-hepatotoxic effect of herbal compounds: a metabolic mechanism perspective. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2024, Volume: 122 Topics: Chemical and Drug Induced Liver Injury; Isoniazid; Liver; Plant Extracts; Plants, Medicinal; Silymar	2024
Fatal Isoniazid Hepatotoxicity in the Deployed Environment. Military medicine, 2021, 05-03, Volume: 186, Issue:5-6 Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Latent Tuberculosi	2021
Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis. Annals of internal medicine, 2017, Aug-15, Volume: 167, Issue:4 Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Drug Combinations; Huma	2017
A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection. Pharmacoepidemiology and drug safety, 2018, Volume: 27, Issue:6 Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Dose-Respon	2018
Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review. British journal of clinical pharmacology, 2018, Volume: 84, Issue:8 Topics: Africa; Anti-HIV Agents; Antitubercular Agents; Asia; Body Weight; Central Nervous System Diseases;	2018
Pharmacogenetic association between Bioscience reports, 2019, 01-31, Volume: 39, Issue:1 Topics: Alleles; Antitubercular Agents; Arylamine N-Acetyltransferase; Chemical and Drug Induced Liver Injur	2019
Pharmacokinetics of isoniazid: The good, the bad, and the alternatives. Tuberculosis (Edinburgh, Scotland), 2019, Volume: 116S Topics: Animals; Antitubercular Agents; Biotransformation; Chemical and Drug Induced Liver Injury; Clinical	2019
Fluoroquinolones for the treatment of latent World journal of gastroenterology, 2019, Jul-14, Volume: 25, Issue:26 Topics: Allografts; Antitubercular Agents; Chemical and Drug Induced Liver Injury; End Stage Liver Disease;	2019
Drug-induced liver injury. Mayo Clinic proceedings, 2014, Volume: 89, Issue:1 Topics: Adult; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Causality; Chemical and Drug Induced Li	2014
Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis. The Cochrane database of systematic reviews, 2014, Mar-04, Issue:3 Topics: Antibiotic Prophylaxis; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Hepatitis B;	2014
Mechanisms of isoniazid-induced idiosyncratic liver injury: emerging role of mitochondrial stress. Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:4 Topics: Animals; Antitubercular Agents; Arylamine N-Acetyltransferase; Chemical and Drug Induced Liver Injur	2014
Treatment of latent tuberculosis infection: a network meta-analysis. Annals of internal medicine, 2014, Sep-16, Volume: 161, Issue:6 Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Drug Th	2014
Pharmacogenetics of isoniazid-induced hepatotoxicity. Drug metabolism reviews, 2015, Volume: 47, Issue:2 Topics: Antitubercular Agents; Arylamine N-Acetyltransferase; Chemical and Drug Induced Liver Injury; Cytoch	2015
Hepatotoxicity mechanisms of isoniazid: A mini-review. Journal of applied toxicology : JAT, 2015, Volume: 35, Issue:12 Topics: Antitubercular Agents; Apoptosis; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Sy	2015
The chemical, genetic and immunological basis of idiosyncratic drug-induced liver injury. Human & experimental toxicology, 2015, Volume: 34, Issue:12 Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Chemical and Drug Induced Liver Injury; Flox	2015
Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis. Pharmacogenomics, 2015, Volume: 16, Issue:18 Topics: Acetylation; Antitubercular Agents; Arylamine N-Acetyltransferase; Chemical and Drug Induced Liver I	2015
Mechanism of isoniazid-induced hepatotoxicity: then and now. British journal of clinical pharmacology, 2016, Volume: 81, Issue:6 Topics: Antitubercular Agents; Biotransformation; Chemical and Drug Induced Liver Injury; Humans; Isoniazid	2016
[Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials]. Enfermedades infecciosas y microbiologia clinica, 2010, Volume: 28, Issue:4 Topics: Anti-HIV Agents; Antibiotic Prophylaxis; Antitubercular Agents; Chemical and Drug Induced Liver Inju	2010
The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2009, Volume: 13, Issue:9 Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Evidence-Based Medicine; Hepatitis B,	2009
Treatment of latent tuberculosis infection: An update. Respirology (Carlton, Vic.), 2010, Volume: 15, Issue:4 Topics: Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Animals; Antitubercular Agent	2010
Drug-induced liver injury: past, present and future. Pharmacogenomics, 2010, Volume: 11, Issue:5 Topics: Alleles; Amoxicillin-Potassium Clavulanate Combination; Arylamine N-Acetyltransferase; Chemical and	2010
Predicting and preventing acute drug-induced liver injury: what's new in 2010? Expert opinion on drug metabolism & toxicology, 2010, Volume: 6, Issue:9 Topics: Acetaminophen; Adult; Aged; Aging; Alanine Transaminase; Amoxicillin-Potassium Clavulanate Combinati	2010
Treatment of latent infection with Mycobacterium tuberculosis: update 2010. The European respiratory journal, 2011, Volume: 37, Issue:3 Topics: Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Communicable Disease Control; Drug	2011
Liver injury caused by drugs: an update. Swiss medical weekly, 2010, Volume: 140 Topics: Acetaminophen; Adaptive Immunity; Analgesics, Non-Narcotic; Antitubercular Agents; Apoptosis; Chemic	2010
Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2010, Volume: 14, Issue:11 Topics: Age Factors; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Laten	2010
A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clinical pharmacology and therapeutics, 2011, Volume: 89, Issue:6 Topics: Animals; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Humans; Isoniazid; Risk Fac	2011
Genetic association studies in drug-induced liver injury. Drug metabolism reviews, 2012, Volume: 44, Issue:1 Topics: Antitubercular Agents; Case-Control Studies; Chemical and Drug Induced Liver Injury; Drug-Related Si	2012
[Drug-induced liver injury]. Recenti progressi in medicina, 2012, Volume: 103, Issue:2 Topics: Acetaminophen; Algorithms; Amoxicillin; Analgesics, Non-Narcotic; Anesthetics, Inhalation; Anti-Bact	2012
Clinical inquiries. Are liver function tests required for patients taking isoniazid for latent TB? The Journal of family practice, 2004, Volume: 53, Issue:1 Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Liver Function Tes	2004
Considering the role of four months of rifampin in the treatment of latent tuberculosis infection. American journal of respiratory and critical care medicine, 2004, Oct-15, Volume: 170, Issue:8 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Chemical and Drug Induced Liver Injury;	2004
Drug-induced hepatotoxicity: 2005. Journal of clinical gastroenterology, 2005, Volume: 39, Issue:4 Suppl 2 Topics: Acetaminophen; Chemical and Drug Induced Liver Injury; Chromans; Female; Humans; Hydroxymethylglutar	2005
Antituberculosis drugs and hepatotoxicity. Respirology (Carlton, Vic.), 2006, Volume: 11, Issue:6 Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Dru	2006
[Systematic review of anti-tuberculosis drug induced adverse reactions in China]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2007, Volume: 30, Issue:6 Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; China; Drug-Related Side Effects and	2007
Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. Journal of gastroenterology and hepatology, 2008, Volume: 23, Issue:2 Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Humans; In	2008
[Nature of the hepatotoxic action of isoniazid (review of the literature)]. Vrachebnoe delo, 1984, Issue:1 Topics: Acetyltransferases; Adult; Aged; Autoimmune Diseases; Biotransformation; Chemical and Drug Induced L	1984
The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis. Tubercle, 1984, Volume: 65, Issue:3 Topics: Acetylation; Chemical and Drug Induced Liver Injury; Homozygote; Humans; Isoniazid; Jaundice; Phenot	1984
Aging and tuberculosis. Gerontology, 1984, Volume: 30, Issue:5 Topics: Aged; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Ethambutol; Female; Humans;	1984
[Toxicity of pyrazinamide in antituberculous treatments (author's transl)]. Revue francaise des maladies respiratoires, 1980, Volume: 8, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Diarrhea; Drug Eruptions; Gout; Humans; Isoniazid; Nausea; P	1980
[Treatment of tuberculous meningitis in adults: current trends and problems]. Revista clinica espanola, 1982, Sep-30, Volume: 166, Issue:6 Topics: Aminosalicylic Acid; Antitubercular Agents; Blood-Brain Barrier; Chemical and Drug Induced Liver Inj	1982
Drug-induced liver injury. The Netherlands journal of medicine, 1980, Volume: 23, Issue:1 Topics: Age Factors; Bile; Biotransformation; Chemical and Drug Induced Liver Injury; Dose-Response Relation	1980
Tuberculosis in the 1980s. The New England journal of medicine, 1980, Jun-26, Volume: 302, Issue:26 Topics: Adult; Antitubercular Agents; BCG Vaccine; Chemical and Drug Induced Liver Injury; Drug Resistance;	1980
Tuberculosis. The Medical clinics of North America, 1980, Volume: 64, Issue:3 Topics: Alcohol Drinking; Carrier State; Chemical and Drug Induced Liver Injury; Ethambutol; Humans; Isoniaz	1980
Drug-related acute and chronic hepatitis. Clinics in gastroenterology, 1980, Volume: 9, Issue:1 Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Drug Hypersen	1980
[Review of the current state of knowledge on prophylactic use of INH]. Pneumonologia polska, 1980, Volume: 48, Issue:8 Topics: Adolescent; Adult; Age Factors; Chemical and Drug Induced Liver Injury; Child; Clinical Trials as To	1980
Drug-induced liver disease. Primary care, 1981, Volume: 8, Issue:2 Topics: Analgesics; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Chlorpromazine; Contracep	1981
Chemoprophylaxis against tuberculosis. Clinics in chest medicine, 1980, Volume: 1, Issue:2 Topics: Adult; Age Factors; Animals; Chemical and Drug Induced Liver Injury; Guinea Pigs; Humans; Isoniazid;	1980
Preventive therapy for tuberculosis in HIV infection: the promise and the reality. AIDS (London, England), 1995, Volume: 9, Issue:7 Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Chemical and Drug Induced Liver	1995
Hepatotoxicity: newer aspects of pathogenesis and treatment. The Gastroenterologist, 1995, Volume: 3, Issue:2 Topics: Acetaminophen; Acetylcysteine; Adenoma, Liver Cell; Adult; Amoxicillin; Anabolic Agents; Beverages;	1995
Hepatotoxicity and transaminase measurement during isoniazid chemoprophylaxis in children. The Pediatric infectious disease journal, 1995, Volume: 14, Issue:2 Topics: Adolescent; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Female; Humans; Inciden	1995
Treatment of hepatic failure secondary to isoniazid hepatitis with liver transplantation. Digestive diseases and sciences, 1994, Volume: 39, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Female; Hepatic Encephalopathy; H	1994
Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis. The Western journal of medicine, 1993, Volume: 159, Issue:5 Topics: Adult; Age Factors; Aged; Cause of Death; Chemical and Drug Induced Liver Injury; Drug Combinations;	1993
A review of isoniazid-related hepatotoxicity during chemoprophylaxis. Australian and New Zealand journal of medicine, 1999, Volume: 29, Issue:3 Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Decision Support Techniques; Humans;	1999
Mycobacterium tuberculosis infection in pediatric liver transplant recipients. The Pediatric infectious disease journal, 2000, Volume: 19, Issue:7 Topics: Adolescent; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child, Preschool; Hemorrh	2000
[Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients]. Kekkaku : [Tuberculosis], 2001, Volume: 76, Issue:1 Topics: Animals; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; E	2001
[Antitubercular drug-induced liver injuries]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 1998, Volume: 21, Issue:5 Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Rifampin; Tubercul	1998
Antitubercular drugs (isoniazid, rifampin and pyrazinamide): hepatobiliary reactions. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2001, Oct-02, Volume: 165, Issue:7 Topics: Antitubercular Agents; Biliary Tract Diseases; Chemical and Drug Induced Liver Injury; Humans; Isoni	2001
[Hepatitis-like liver disorders caused by infections, poisoning and drugs]. Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1976, Volume: 82 Pt 1 Topics: Alcoholism; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Cytomegalovirus Infection	1976
Toxicity of antibacterial agents: mechanism of action on mammalian cells. Annual review of pharmacology and toxicology, 1979, Volume: 19 Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Carbohydrate Metabolism; Cel	1979
Drug metabolism in the production of liver injury. The Medical clinics of North America, 1975, Volume: 59, Issue:4 Topics: Acetaminophen; Acetanilides; Alkylating Agents; Bromobenzenes; Chemical and Drug Induced Liver Injur	1975
Drug-induced chronic liver disease. Gastroenterology, 1977, Volume: 72, Issue:6 Topics: Chemical and Drug Induced Liver Injury; Chronic Disease; Halothane; Humans; Indoles; Isoniazid; Meth	1977
The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle, 1978, Volume: 59, Issue:1 Topics: Acetylation; Adolescent; Adult; Aged; Chemical and Drug Induced Liver Injury; Clinical Trials as Top	1978
[Drug induced liver disease (author's transl)]. Therapeutische Umschau. Revue therapeutique, 1978, Volume: 35, Issue:9 Topics: Azathioprine; Bile Acids and Salts; Bilirubin; Biotransformation; Chemical and Drug Induced Liver In	1978
Hepatotoxicity: pathogenesis and therapeutic intervention. Clinics in gastroenterology, 1979, Volume: 8, Issue:1 Topics: Acetaminophen; Anabolic Agents; Androgens; Animals; Chemical and Drug Induced Liver Injury; Cysteami	1979
[Drug-induced active hepatitis (author's transl)]. La Nouvelle presse medicale, 1979, Jun-02, Volume: 8, Issue:24 Topics: Chemical and Drug Induced Liver Injury; Drug Hypersensitivity; Female; Humans; Indoles; Isoniazid; M	1979
The role of metabolism in the hepatotoxicity of isoniazid and iproniazid. Drug metabolism reviews, 1979, Volume: 10, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cobalt; Humans; Hydrazines; Iproniazid; Isoniazid;	1979
Drug-induced chronic hepatitis and cirrhosis. Progress in liver diseases, 1979, Volume: 6 Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adve	1979
Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Annals of internal medicine, 1976, Volume: 84, Issue:2 Topics: Acetylation; Adult; Aged; Alanine Transaminase; Animals; Antibodies, Antinuclear; Aspartate Aminotra	1976
Metabolic activation: biochemical basis for many drug-induced liver injuries. Progress in liver diseases, 1976, Volume: 5 Topics: Acetaminophen; Animals; Binding Sites; Carcinogens; Chemical and Drug Induced Liver Injury; Drug Hyp	1976
Drug metabolism in liver disease. Journal of clinical pathology. Supplement (Royal College of Pathologists), 1975, Volume: 9 Topics: Acetaminophen; Acute Disease; Antipyrine; Chemical and Drug Induced Liver Injury; Chronic Disease; H	1975
[Isoniazide hepatic damage as opposed to prophylactic treatment for tuberculosis]. Harefuah, 1992, Feb-16, Volume: 122, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Tuberculosis	1992
Isoniazid-associated hepatitis deaths: a review of available information. The American review of respiratory disease, 1992, Volume: 145, Issue:2 Pt 1 Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Female; Humans; Isoniazid; Male; Middle Aged; U	1992
Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest, 1991, Volume: 99, Issue:2 Topics: Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Humans; Isoniazid; Meta-Analysis	1991
[Adverse effects of antitubercular agents]. Zhonghua jie he he hu xi xi ji bing za zhi = Chinese journal of tuberculosis and respiratory diseases, 1985, Volume: 8, Issue:6 Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Hearing Loss, Bilateral; Humans; Immu	1985
Antituberculosis agents. The Medical clinics of North America, 1988, Volume: 72, Issue:3 Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Ethambutol	1988
[Definition and classification of toxic hepatitis]. Nihon rinsho. Japanese journal of clinical medicine, 1985, Volume: 43, Issue:6 Topics: Animals; Chemical and Drug Induced Liver Injury; Chlorpromazine; Contraceptive Agents; Female; Hepat	1985
[Toxic hepatitis induced by antibiotics]. Nihon rinsho. Japanese journal of clinical medicine, 1985, Volume: 43, Issue:6 Topics: Anti-Bacterial Agents; Chemical and Drug Induced Liver Injury; Chloramphenicol; Erythromycin Estolat	1985
[Prevention and therapy of severe toxic hepatitis]. Nihon rinsho. Japanese journal of clinical medicine, 1985, Volume: 43, Issue:6 Topics: Chemical and Drug Induced Liver Injury; Chlorpromazine; Halothane; Humans; Isoniazid; Methyldopa; Pe	1985
[Drug damage to the liver: role of reactive metabolites and pharmacokinetics]. Schweizerische medizinische Wochenschrift, 1985, Sep-21, Volume: 115, Issue:38 Topics: Acetaminophen; Amiodarone; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adv	1985
[Possibilities of liver damage by foreign substances]. Die Pharmazie, 1985, Volume: 40, Issue:11 Topics: Aminopyrine; Animals; Antimetabolites; Carcinogens; Chemical and Drug Induced Liver Injury; Chemical	1985
Modern trends in chemoprophylaxis in tuberculosis. Le Journal medical libanais. The Lebanese medical journal, 1973, Volume: 26, Issue:2 Topics: Adult; Age Factors; Animals; BCG Vaccine; Chemical and Drug Induced Liver Injury; Child; Humans; Iso	1973
Preventive therapy of tuberculosis. Annual review of medicine, 1974, Volume: 25 Topics: Adolescent; Adult; Alcoholism; BCG Vaccine; Chemical and Drug Induced Liver Injury; Child; Clinical	1974
Postoperative juandice. The Surgical clinics of North America, 1974, Volume: 54, Issue:3 Topics: Aminosalicylic Acids; Anemia, Hemolytic; Bile Ducts; Bilirubin; Chemical and Drug Induced Liver Inju	1974
[Liver diseases induced by drugs]. Revista clinica espanola, 1967, Aug-15, Volume: 106, Issue:3 Topics: Animals; Arsenicals; Chemical and Drug Induced Liver Injury; Chloroform; Chlorpromazine; Contracepti	1967
More about isonicotinic acid hydrazide toxicity. Food and cosmetics toxicology, 1970, Volume: 8, Issue:5 Topics: Adenocarcinoma; Adenofibroma; Adenoma; Animals; Carcinoma; Chemical and Drug Induced Liver Injury; C	1970
[Current status of chemotherapy of pulmonary tuberculosis and its further prospectives]. Zeitschrift fur Erkrankungen der Atmungsorgane mit Folia bronchologica, 1971, Volume: 134, Issue:2 Topics: Aminosalicylic Acids; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Cycloserine; Dr	1971

Article	Year
Association of UGT2B7 polymorphisms with risk of induced liver injury by anti-tuberculosis drugs in Chinese Han. International journal of immunopathology and pharmacology, 2017, Volume: 30, Issue:4 Topics: Adult; Antitubercular Agents; Asian People; Chemical and Drug Induced Liver Injury; Drug Therapy, Co	2017
Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial. Journal of acquired immune deficiency syndromes (1999), 2018, 05-01, Volume: 78, Issue:1 Topics: Adult; Alanine Transaminase; Anti-Retroviral Agents; Antitubercular Agents; Aspartate Aminotransfera	2018
Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: A prospective randomized open-label study. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2019, Volume: 25, Issue:12 Topics: Age Factors; Aged, 80 and over; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug	2019
Selected pharmaceutical excipient prevent isoniazid and rifampicin induced hepatotoxicity. Current drug metabolism, 2013, Volume: 14, Issue:6 Topics: Adult; Animals; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP2	2013
Isoniazid-associated hepatitis in adults infected with HIV receiving 36 months of isoniazid prophylaxis in Botswana. Chest, 2015, Volume: 147, Issue:5 Topics: Adult; Antitubercular Agents; Botswana; Chemical and Drug Induced Liver Injury; Double-Blind Method;	2015
Isoniazid-associated hepatitis in adults infected with HIV receiving 36 months of isoniazid prophylaxis in Botswana. Chest, 2015, Volume: 147, Issue:5 Topics: Adult; Antitubercular Agents; Botswana; Chemical and Drug Induced Liver Injury; Double-Blind Method;	2015
Isoniazid-associated hepatitis in adults infected with HIV receiving 36 months of isoniazid prophylaxis in Botswana. Chest, 2015, Volume: 147, Issue:5 Topics: Adult; Antitubercular Agents; Botswana; Chemical and Drug Induced Liver Injury; Double-Blind Method;	2015
Isoniazid-associated hepatitis in adults infected with HIV receiving 36 months of isoniazid prophylaxis in Botswana. Chest, 2015, Volume: 147, Issue:5 Topics: Adult; Antitubercular Agents; Botswana; Chemical and Drug Induced Liver Injury; Double-Blind Method;	2015
Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2015, Volume: 19, Issue:9 Topics: Adult; Antitubercular Agents; Aspartate Aminotransferases; Brazil; Canada; Case-Control Studies; Che	2015
Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2015, Volume: 19, Issue:9 Topics: Adult; Antitubercular Agents; Aspartate Aminotransferases; Brazil; Canada; Case-Control Studies; Che	2015
Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2015, Volume: 19, Issue:9 Topics: Adult; Antitubercular Agents; Aspartate Aminotransferases; Brazil; Canada; Case-Control Studies; Che	2015
Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2015, Volume: 19, Issue:9 Topics: Adult; Antitubercular Agents; Aspartate Aminotransferases; Brazil; Canada; Case-Control Studies; Che	2015
Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection. Internal medicine journal, 2016, Volume: 46, Issue:3 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug In	2016
Prevention of hepatotoxicity due to anti tuberculosis treatment: a novel integrative approach. World journal of gastroenterology, 2008, Aug-14, Volume: 14, Issue:30 Topics: Adult; Antitubercular Agents; Blood Sedimentation; Body Weight; Chemical and Drug Induced Liver Inju	2008
Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Annals of internal medicine, 2008, Nov-18, Volume: 149, Issue:10 Topics: Adolescent; Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Administratio	2008
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Mar-15, Volume: 50, Issue:6 Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy	2010
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Mar-15, Volume: 50, Issue:6 Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy	2010
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Mar-15, Volume: 50, Issue:6 Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy	2010
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Mar-15, Volume: 50, Issue:6 Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy	2010
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Mar-15, Volume: 50, Issue:6 Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy	2010
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Mar-15, Volume: 50, Issue:6 Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy	2010
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Mar-15, Volume: 50, Issue:6 Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy	2010
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Mar-15, Volume: 50, Issue:6 Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy	2010
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Mar-15, Volume: 50, Issue:6 Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy	2010
Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana. American journal of respiratory and critical care medicine, 2010, Jul-15, Volume: 182, Issue:2 Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alcohol Drinking; Anti-Retroviral Agents; Antitubercu	2010
Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana. American journal of respiratory and critical care medicine, 2010, Jul-15, Volume: 182, Issue:2 Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alcohol Drinking; Anti-Retroviral Agents; Antitubercu	2010
Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana. American journal of respiratory and critical care medicine, 2010, Jul-15, Volume: 182, Issue:2 Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alcohol Drinking; Anti-Retroviral Agents; Antitubercu	2010
Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana. American journal of respiratory and critical care medicine, 2010, Jul-15, Volume: 182, Issue:2 Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alcohol Drinking; Anti-Retroviral Agents; Antitubercu	2010
Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:10 Topics: Acetylcysteine; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug Induced Liver Inju	2010
[The association between NAT2 polymorphism and anti-tuberculosis drug-induced hepatitis]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2010, Volume: 18, Issue:6 Topics: Adolescent; Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Chemical and Drug Induced L	2010
Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials. Arthritis care & research, 2013, Volume: 65, Issue:2 Topics: Adult; Aged; Antibodies, Monoclonal; Antitubercular Agents; Arthritis; Chemical and Drug Induced Liv	2013
Safety of long-term isoniazid preventive therapy in children with HIV: a comparison of two dosing schedules. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2013, Volume: 17, Issue:1 Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Chemical and Drug Induced Liver Injury	2013
NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. European journal of clinical pharmacology, 2013, Volume: 69, Issue:5 Topics: Adult; Animals; Antitubercular Agents; Arylamine N-Acetyltransferase; Asian People; Chemical and Dru	2013
Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Annals of internal medicine, 2002, Oct-15, Volume: 137, Issue:8 Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Chemical and Drug Induced Liver Injury; D	2002
Isoniazid prevention of tuberculosis. Lancet (London, England), 1983, Feb-19, Volume: 1, Issue:8321 Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Double-Blind Method;	1983
New data on preventive treatment with isoniazid. Annals of internal medicine, 1983, Volume: 98, Issue:5 Pt 1 Topics: Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Administration Schedule; Huma	1983
Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis. The American review of respiratory disease, 1984, Volume: 129, Issue:1 Topics: Acetylation; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Humans; India; Isonia	1984
Six-months isoniazid-rifampin therapy for pulmonary tuberculosis. Report of a United States Public Health Service Cooperative Trial. The American review of respiratory disease, 1984, Volume: 129, Issue:4 Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Double-Blind Method;	1984
[Pyrazinamide versus ethambutol in short-term therapy of lung tuberculosis. A randomized study]. Schweizerische medizinische Wochenschrift, 1983, Dec-24, Volume: 113, Issue:51 Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Ethambutol; Humans;	1983
Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bulletin of the World Health Organization, 1982, Volume: 60, Issue:4 Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Europe, Eastern; Fema	1982
Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. A controlled clinical study. Tubercle, 1980, Volume: 61, Issue:1 Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Clinical Tri	1980
Rifampin-isoniazid therapy of alcoholic and nonalcoholic tuberculous patients in a U.S. Public Health Service Cooperative Therapy Trial. The American review of respiratory disease, 1980, Volume: 122, Issue:2 Topics: Alcoholism; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Clinical Trials as	1980
[Review of the current state of knowledge on prophylactic use of INH]. Pneumonologia polska, 1980, Volume: 48, Issue:8 Topics: Adolescent; Adult; Age Factors; Chemical and Drug Induced Liver Injury; Child; Clinical Trials as To	1980
Short-course chemotherapy. The Arkansas experience. Chest, 1981, Volume: 80, Issue:6 Topics: Adolescent; Adult; Aged; Arkansas; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic;	1981
Ethambutol compared to rifampin in original treatment of pulmonary tuberculosis. Lung, 1980, Volume: 157, Issue:3 Topics: Adolescent; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Ethambutol; Humans; I	1980
Antituberculosis treatment-induced hepatotoxicity: role of predictive factors. Postgraduate medical journal, 1995, Volume: 71, Issue:836 Topics: Adolescent; Adult; Antitubercular Agents; Body Mass Index; Case-Control Studies; Chemical and Drug I	1995
Hepatic enzyme abnormalities in children on triple therapy for tuberculosis. Pediatric pulmonology, 1999, Volume: 27, Issue:1 Topics: Adolescent; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Child, Preschool;	1999
U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. The American review of respiratory disease, 1979, Volume: 119, Issue:6 Topics: Adolescent; Adult; Aged; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Drug E	1979
U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. The American review of respiratory disease, 1979, Volume: 119, Issue:6 Topics: Adolescent; Adult; Aged; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Drug E	1979
U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. The American review of respiratory disease, 1979, Volume: 119, Issue:6 Topics: Adolescent; Adult; Aged; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Drug E	1979
U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. The American review of respiratory disease, 1979, Volume: 119, Issue:6 Topics: Adolescent; Adult; Aged; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Drug E	1979
Isoniazid chemoprophylaxis. Association with detection and incidence of liver toxicity. Archives of internal medicine, 1977, Volume: 137, Issue:9 Topics: Adult; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic	1977
[Hepatoxic side-effects of rifampicin. A comparative clinical study]. Die Medizinische Welt, 1977, Nov-25, Volume: 28, Issue:47 Topics: Alanine Transaminase; Alcoholism; Alkaline Phosphatase; Aspartate Aminotransferases; Chemical and Dr	1977
The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle, 1978, Volume: 59, Issue:1 Topics: Acetylation; Adolescent; Adult; Aged; Chemical and Drug Induced Liver Injury; Clinical Trials as Top	1978
Containment of tuberculosis. Preventive therapy with isoniazid, and contact investigation. Chest, 1979, Volume: 76, Issue:6 Suppl Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Epidemiologic Methods	1979
[Hepatotoxic side-effects of rifampicin; a comparative clinical study (author's transl)]. Praxis und Klinik der Pneumologie, 1977, Volume: 31, Issue:11 Topics: Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoni	1977
Does isoniazid increase the hepatotoxicity of the combination prothionamide-dapsone? Isoprodian Study Group. International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association, 1992, Volume: 60, Issue:4 Topics: Adolescent; Adult; Chemical and Drug Induced Liver Injury; Dapsone; Double-Blind Method; Drug Combin	1992
A controlled clinical trial of 3- and 5-month regimens in the treatment of sputum-positive pulmonary tuberculosis in South India. Tuberculosis Research Centre, Madras, and National Tuberculosis Institute, Bangalore. The American review of respiratory disease, 1986, Volume: 134, Issue:1 Topics: Adolescent; Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as	1986
[Which is the best drug combination for the short-term therapy of tuberculosis? A prospective randomized study with 190 patients]. Schweizerische medizinische Wochenschrift, 1985, Sep-28, Volume: 115, Issue:39 Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug	1985
Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East Africa--fifth investigation. A co-operative study in East African hospitals, clinics and laboratories with the collaboration of the East African and British Med Tubercle, 1970, Volume: 51, Issue:2 Topics: Adolescent; Adult; Africa, Eastern; Aged; Chemical and Drug Induced Liver Injury; Clinical Trials as	1970
Co-operative controlled trial of a standard regimen of streptomycin, PAS and isoniazid and three alternative regimens of chemotherapy in Britain. A report from the British Medical Research Council. Tubercle, 1973, Volume: 54, Issue:2 Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Chemical and Drug Induced Liver Injury; Clinical Tria	1973
[Rifampicin in the treatment of active pulmonary tuberculosis. Controlled trial of isoniazid-rifampicin-thiocarlide versus isoniazid-streptomycin-thiocarlide in untreated tuberculosis. Treatment of relapses with the combination rifampicin-ethambutol-thioc Schweizerische medizinische Wochenschrift, 1974, Mar-09, Volume: 104, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Hypersensitivity; Drug Therap	1974
Preventive therapy of tuberculosis. Annual review of medicine, 1974, Volume: 25 Topics: Adolescent; Adult; Alcoholism; BCG Vaccine; Chemical and Drug Induced Liver Injury; Child; Clinical	1974
[Side effects of isoniazid]. Bulletin of the International Union against Tuberculosis, 1974, Volume: 49, Issue:1 Topics: Adult; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Ga	1974
[Preliminary clinical experiments with thioamid of alpha-propyl-isonocotinic acid (Trevintix) in pulmonary tuberculosis]. Gruzlica i choroby pluc; tuberculosis et pneumonologia, 1969, Volume: 37, Issue:4 Topics: Adolescent; Adult; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Tolerance;	1969
Chemoprophylaxis of tuberculosis: when is the benefit worth the risk and cost? Annals of internal medicine, 1971, Volume: 74, Issue:5 Topics: Adolescent; Adult; Chemical and Drug Induced Liver Injury; Child; Costs and Cost Analysis; Denmark;	1971